# ë°°ê²½ ìë£Œ: Session 2 - Bacterial Pathogenesis

**ì„¸ì…˜**: Session 2: Bacterial Pathogenesis
**ì—°ì‚¬**: Sung Jae Shin (Yonsei Univ.), You-Hee Cho (CHA Univ.), Wonsik Lee (SKKU)
**ì¼ì‹œ**: 2025ë…„ 10ì›” 30ì¼ (ëª©) 13:40-14:55
**ì¥ì†Œ**: ì„±ê· ê´€ëŒ€í•™êµ ì˜ê³¼ëŒ€í•™, AI ê°•ì˜ì‹¤ 3304

**ì¤‘ìš”ë„**: â­â­â­â­â­ (95/100ì )

---

## ğŸ¯ ì„¸ì…˜ ê°œìš”

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

**1. í•œêµ­ì˜ ì£¼ìš” ë³‘ì›ì„± ì„¸ê·  ë¬¸ì œë¥¼ ë‹¤ë£¬ë‹¤**
- ê²°í•µê· (MTB)ê³¼ ë¹„ê²°í•µí•­ì‚°ê· (NTM)ì€ í•œêµ­ì—ì„œ ê¸‰ì¦í•˜ëŠ” ê³µì¤‘ë³´ê±´ ë¬¸ì œ
- 2014ë…„ 2.7%ì—ì„œ 2019ë…„ 4.8%ë¡œ NTM ë¶„ë¦¬ìœ¨ ì¦ê°€
- MAC(Mycobacterium avium complex) ê°ì—¼ì€ ê³ ë ¹í™”ì™€ í•¨ê»˜ ì¦ê°€ ì¶”ì„¸
- í•œêµ­ íŠ¹ì´ì  ì—­í•™ ë°ì´í„°ì™€ ì¹˜ë£Œ ì „ëµ í•„ìš”

**2. ì°¨ì„¸ëŒ€ í•­ê·  ì „ëµì˜ ìƒˆë¡œìš´ íŒ¨ëŸ¬ë‹¤ì„ì„ ì œì‹œí•œë‹¤**
- ê¸°ì¡´ í•­ìƒì œ ë‚´ì„± ê·¹ë³µì„ ìœ„í•œ ROS(í™œì„±ì‚°ì†Œì¢…) ê¸°ë°˜ ì ‘ê·¼ë²•
- Pharmacophore ê°œë…ì„ í™œìš©í•œ ì„ íƒì  ì‚°í™” ìŠ¤íŠ¸ë ˆìŠ¤ ìœ ë„
- MDR ì„¸ê· ì— íš¨ê³¼ì ì¸ ë¹„í•­ìƒì œ ì¹˜ë£Œ ì˜µì…˜
- 2024ë…„ ìµœì‹  ì—°êµ¬: organoruthenium complexë¥¼ ì´ìš©í•œ ê·¸ëŒì–‘ì„±ê·  íŠ¹ì´ì  ROS ìƒì„±

**3. í™©ìƒ‰í¬ë„ìƒêµ¬ê· ì˜ ìƒˆë¡œìš´ ì¹˜ë£Œ í‘œì ì„ ë°œêµ´í•œë‹¤**
- MRSAëŠ” ì „ ì„¸ê³„ì ìœ¼ë¡œ ê°€ì¥ ì¤‘ìš”í•œ ë‚´ì„±ê·  ì¤‘ í•˜ë‚˜
- Transposon sequencingìœ¼ë¡œ ë‹¤ì–‘í•œ ê°ì—¼ í™˜ê²½ì—ì„œì˜ ìƒì¡´ ì „ëµ ê·œëª…
- ì„¸í¬ ë‚´, í˜ˆë¥˜, ì¡°ì§ íŠ¹ì´ì  ì ì‘ ë©”ì»¤ë‹ˆã‚ºï¿½ ì°¨ì´ ë°œê²¬
- ê¸°ì¡´ í•­ìƒì œë¥¼ ë„˜ì–´ì„  ìƒˆë¡œìš´ í‘œì (DHQD, Sortase A, serine hydrolases) ì œì‹œ

**4. í¬ë‹¥ ì—°êµ¬ìì—ê²Œ í•„ìˆ˜ì ì¸ ì—°êµ¬ ë°©ë²•ë¡ ê³¼ í˜‘ì—… ê¸°íšŒë¥¼ ì œê³µí•œë‹¤**
- ì „ì„ìƒ ëª¨ë¸(ë§ˆìš°ìŠ¤, ì˜¤ê°€ë…¸ì´ë“œ) í™œìš© ì „ëµ
- High-throughput screening í”Œë«í¼ êµ¬ì¶• ê²½í—˜
- ê¸°ì´ˆ-ì„ìƒ-ì‚°ì—… ì—°ê³„ ì—°êµ¬ ì‚¬ë¡€
- êµ­ì œ í˜‘ë ¥(ì‚°í•™ì—°) ë„¤íŠ¸ì›Œí‚¹ ê¸°íšŒ

---

## ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (ì„¸ì…˜ ì „ì²´)

### ì´ ì„¸ì…˜ì€ ì‰½ê²Œ ë§í•˜ë©´...

**í•œ ì¤„ ìš”ì•½**: "í•œêµ­ì—ì„œ ë¬¸ì œë˜ëŠ” ì£¼ìš” ë³‘ì›ì„± ì„¸ê· (ê²°í•µê· , í¬ë„ìƒêµ¬ê· )ì„ ì–´ë–»ê²Œ ì´í•´í•˜ê³ , ì–´ë–»ê²Œ ìƒˆë¡œìš´ ë°©ì‹ìœ¼ë¡œ ì¡ì„ ê²ƒì¸ê°€ì— ëŒ€í•œ ìµœì‹  ì—°êµ¬ ì „ëµ ê³µìœ "

### ğŸ¬ ì„¸ê·  ë³‘ì›ì„±ì˜ ì´í•´ì™€ ê·¹ë³µ - ì´ì•¼ê¸°ë¡œ ì´í•´í•˜ê¸°

**[1ì¥: ìœ„ê¸°ì˜ ì‹œì‘ - í•­ìƒì œê°€ ë“£ì§€ ì•ŠëŠ” ì‹œëŒ€]**

**ë°°ê²½**: í•œêµ­ì˜ ê°ì—¼ë³‘ ì§€í˜• ë³€í™”

2000ë…„ëŒ€ ì´ˆë°˜ë§Œ í•´ë„ ê²°í•µì€ "ê³¼ê±°ì˜ ë³‘"ìœ¼ë¡œ ì—¬ê²¨ì¡ŒìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 2010ë…„ëŒ€ ë“¤ì–´ ìƒˆë¡œìš´ ë¬¸ì œê°€ ë“±ì¥í–ˆìŠµë‹ˆë‹¤.

```
ë¬¸ì œ 1: ë¹„ê²°í•µí•­ì‚°ê· (NTM) ê°ì—¼ ê¸‰ì¦
- 2014ë…„: í˜¸í¡ê¸° ê²€ì²´ì˜ 2.7%ì—ì„œ NTM ë¶„ë¦¬
- 2019ë…„: 4.8%ë¡œ ì¦ê°€ (ê±°ì˜ 2ë°°!)
- ì£¼ìš” ì›ì¸ê· : M. avium (41%), M. intracellulare (38%), M. abscessus (9%)

ë¬¸ì œ 2: ê³ ë ¹í™”ì™€ ë§Œì„± íì§ˆí™˜
- í‰ê·  ì—°ë ¹ 61.5ì„¸, ì—¬ì„±ì´ 57.7%
- ê¸°ì¡´ íì§ˆí™˜ ìˆìœ¼ë©´ ì¹˜ë£Œë¹„ ê¸‰ì¦
- M. abscessus ê°ì—¼ ì‹œ ì˜ë£Œë¹„ ì¤‘ì•™ê°’ US $5,044 (49.7ê°œì›” ì¶”ì )

ë¬¸ì œ 3: í™©ìƒ‰í¬ë„ìƒêµ¬ê· (S. aureus)ì˜ ë‹¤ë©´ì„±
- í”¼ë¶€ í‘œë©´ë¶€í„° í˜ˆë¥˜, ë¼ˆ, íê¹Œì§€ ì¹¨íˆ¬
- MRSA(ë©”í‹°ì‹¤ë¦° ë‚´ì„±)ëŠ” ê¸°ë³¸, VRSA(ë°˜ì½”ë§ˆì´ì‹  ë‚´ì„±)ë„ ì¶œí˜„
- í™˜ê²½ë§ˆë‹¤ ë‹¤ë¥¸ ìƒì¡´ ì „ëµ ì‚¬ìš© â†’ í•œ ê°€ì§€ ì•½ìœ¼ë¡œ ì•ˆ ì¡í˜
```

**ì „í™˜ì **: ì„¸ ê°€ì§€ ìƒˆë¡œìš´ ì ‘ê·¼ë²•ì˜ ë“±ì¥

2020ë…„ëŒ€ ì¤‘ë°˜, ì—°êµ¬ìë“¤ì€ "ì„¸ê· ì„ ì£½ì´ëŠ” ë°©ë²•"ì„ ê·¼ë³¸ì ìœ¼ë¡œ ì¬ê³ í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤.

```
ì§ˆë¬¸: ì™œ í•­ìƒì œëŠ” ê³„ì† ë‚´ì„±ì´ ìƒê¸°ëŠ”ê°€?
â†’ ì„¸ê· ì´ íŠ¹ì • ì•½ë¬¼ í‘œì ì— ëŒ€í•œ ëŒì—°ë³€ì´ë¥¼ ë§Œë“¤ê¸° ë•Œë¬¸

ìƒˆë¡œìš´ ì§ˆë¬¸: ì„¸ê· ì´ í”¼í•  ìˆ˜ ì—†ëŠ” ê³µê²©ì€ ë¬´ì—‡ì¸ê°€?
â†’ ì„¸í¬ ìì²´ì˜ ì‚°í™” ìŠ¤íŠ¸ë ˆìŠ¤ (ëª¨ë“  ìƒëª…ì²´ì˜ ì•½ì )
â†’ ì—¬ëŸ¬ í™˜ê²½ì—ì„œ ê³µí†µì ìœ¼ë¡œ í•„ìš”í•œ í•„ìˆ˜ ìœ ì „ì
â†’ ìˆ™ì£¼ ë©´ì—­ì„ íšŒí”¼í•˜ëŠ” íŠ¹ì • ë©”ì»¤ë‹ˆì¦˜ ì°¨ë‹¨
```

**[ë°œê²¬/ì˜ë¯¸]**:
1. **Sung Jae Shin (Yonsei)ì˜ ì ‘ê·¼**: ê²°í•µê· (Mtb)ê³¼ MACì˜ ë³‘ì›ì„±ì´ **ê·¼ë³¸ì ìœ¼ë¡œ ë‹¤ë¥´ë‹¤**ëŠ” ê²ƒì„ ë°í˜
   - Mtb: ëŒ€ì‹ì„¸í¬ ë‚´ ìƒì¡´, Type I IFN ìœ ë„ë¡œ ë©´ì—­ íšŒí”¼
   - MAC: ì§€ë°©ì‚° ëŒ€ì‚¬ ì´ìš©, í ì¡°ì§ì—ì„œ ë‹¤ë¥¸ ë©´ì—­ ë°˜ì‘ ìœ ë„
   - **ì˜ë¯¸**: ê°™ì€ "í•­ì‚°ê· "ì´ë¼ë„ ì¹˜ë£Œ ì „ëµì´ ë‹¬ë¼ì•¼ í•¨

2. **You-Hee Cho (CHA)ì˜ ì ‘ê·¼**: ROSë¥¼ **ë¬´ê¸°**ë¡œ ë§Œë“¤ê¸°
   - Pharmacophore (ì•½ë¦¬ í™œì„± ë¶„ì ê³¨ê²©)ë¡œ ì„ íƒì  ROS ìƒì„±
   - ê·¸ëŒì–‘ì„±ê· ì—ë§Œ íš¨ê³¼ì ì¸ organoruthenium complex ê°œë°œ (2021ë…„ JACS Au)
   - **ì˜ë¯¸**: ì •ìƒ ì„¸í¬ëŠ” ë³´í˜¸í•˜ë©´ì„œ ì„¸ê· ë§Œ ì‚°í™” ìŠ¤íŠ¸ë ˆìŠ¤ë¡œ ì£½ì„

3. **Wonsik Lee (SKKU)ì˜ ì ‘ê·¼**: S. aureusê°€ **í™˜ê²½ë§ˆë‹¤ ë‹¤ë¥¸ ì „ëµ** ì‚¬ìš©
   - ì„¸í¬ ë‚´: Tn sequencingìœ¼ë¡œ ìƒì¡´ í•„ìˆ˜ ìœ ì „ì ê·œëª…
   - í˜ˆë¥˜: ë‹¤ë¥¸ ìœ ì „ì ì„¸íŠ¸ í•„ìš”
   - ì¡°ì§: ë˜ ë‹¤ë¥¸ ì ì‘ ë©”ì»¤ë‹ˆì¦˜
   - **ì˜ë¯¸**: ê° ê°ì—¼ ë¶€ìœ„ì— ë§ëŠ” í‘œì  í•„ìš” (one-size-fits-all ë¶ˆê°€)

**ê²°ë¡ **: "ë³‘ì›ì„± ì„¸ê· ì„ ì´í•´í•˜ëŠ” ê²ƒì€ ê·¸ë“¤ì´ 'ì–´ë–»ê²Œ ì‚¬ëŠ”ê°€'ë¥¼ ì•„ëŠ” ê²ƒì´ë©°, ì´ë¥¼ í†µí•´ 'ì–´ë–»ê²Œ ì£½ì¼ ê²ƒì¸ê°€'ì˜ ë‹µì„ ì°¾ëŠ”ë‹¤."

---

**[2ì¥: ë©”ì»¤ë‹ˆì¦˜ì˜ ì´í•´ - ì„¸ê· ì€ ì–´ë–»ê²Œ ìˆ™ì£¼ë¥¼ ì†ì´ëŠ”ê°€]**

**ì£¼ìš” ê°œë… 1: Mycobacterial Immune Evasion (ë©´ì—­ íšŒí”¼)**

**ì‹¤í—˜/ì—°êµ¬**:
```
Shin ê·¸ë£¹ì˜ ë§ˆìš°ìŠ¤ ëª¨ë¸ ì—°êµ¬:
â†’ C3H/HeJ ë§ˆìš°ìŠ¤ (Mtb ê°ì—¼ ë¯¼ê°)
â†’ A/J ë§ˆìš°ìŠ¤ (MAC ê°ì—¼ ë¯¼ê°)

ë°œê²¬:
- Mtb ê°ì—¼: Neutrophilê³¼ Type I IFNì´ í•µì‹¬
  â†’ Neutrophil ì œê±° ì‹œ: í ë³‘ë³€ ê°ì†Œ
  â†’ Type I IFN ì°¨ë‹¨ ì‹œ: ìƒì¡´ìœ¨ ì¦ê°€

- MAC ê°ì—¼: ì§€ë°©ì‚° ëŒ€ì‚¬ì™€ lipid-associated genes
  â†’ A/J ë§ˆìš°ìŠ¤: í ì§€ë°©ì‚° ìˆ˜ì¹˜ â†‘
  â†’ ë©´ì—­ëŒ€ì‚¬ ê²½ë¡œê°€ ê°ìˆ˜ì„± ê²°ì •

â†’ ê²°ë¡ : ê°™ì€ "í•­ì‚°ê· "ì´ì§€ë§Œ ë©´ì—­ ë°˜ì‘ê³¼ ëŒ€ì‚¬ ê²½ë¡œê°€ ì™„ì „íˆ ë‹¤ë¦„
   â†’ ì¹˜ë£Œ í‘œì ë„ ë‹¬ë¼ì•¼ í•¨ (ë©´ì—­ ì¡°ì ˆ vs ëŒ€ì‚¬ ì–µì œ)
```

**ì˜ë¯¸**:
- MTB ë°±ì‹ /ì¹˜ë£Œ: Th1 ë°˜ì‘ ê°•í™”, Type I IFN ì–µì œ
- MAC ì¹˜ë£Œ: ì§€ë°©ì‚° ëŒ€ì‚¬ ì¡°ì ˆ, dendritic cell ê¸°ëŠ¥ ê°•í™”

**ì£¼ìš” ê°œë… 2: ROS-Mediated Killing (í™œì„±ì‚°ì†Œ ë§¤ê°œ ì‚´ê· )**

```
ROS ìƒì„± ë©”ì»¤ë‹ˆì¦˜:
1. ì •ìƒ í˜¸í¡ ì‹œ: O2 â†’ H2O2 (ì†ŒëŸ‰, í•­ì‚°í™” íš¨ì†Œë¡œ ì œê±°)
2. ìŠ¤íŠ¸ë ˆìŠ¤ ì‹œ: O2 â†’ O2â€¢âˆ’ â†’ H2O2 â†’ â€¢OH (ë…ì„± ì¦ê°€)

ì„¸ê· ì˜ ëŒ€ì‘:
â†’ Antioxidant defense systems (SOD, catalase, peroxidase)
â†’ Oxidative stress response (OxyR, SoxRS regulons)

Cho ê·¸ë£¹ì˜ ì „ëµ:
â†’ Pharmacophore (ì•½ë¬¼ ì‘ìš©ê¸°)ë¡œ ì„¸ê·  "ì•ˆì—ì„œ" ROS ìƒì„±
â†’ Organoruthenium complex: Schiff-base ligand ê²°í•©
â†’ ì„¸í¬ ë‚´ O2ë¥¼ H2O2ë¡œ í™˜ì› (transfer hydrogenation)

ì„ íƒì„±:
â†’ ê·¸ëŒì–‘ì„±ê· : ì„¸í¬ë²½ í†µê³¼ ì‰¬ì›€ â†’ ROS ì¶•ì 
â†’ ê·¸ëŒìŒì„±ê· : ì™¸ë§‰ì´ ì°¨ë‹¨ â†’ ì˜í–¥ ì ìŒ
â†’ ì¸ê°„ ì„¸í¬: ë¯¸í† ì½˜ë“œë¦¬ì•„ì—ì„œ ê²©ë¦¬ â†’ ë…ì„± ë‚®ìŒ

â†’ íš¨ê³¼: P. aeruginosa ë°”ì´ì˜¤í•„ë¦„ â†“, S. aureus ë‚´ì„±ê·  ì‚¬ë©¸
```

**ì˜ë¯¸**:
- MDR ì„¸ê· ì— íš¨ê³¼ì  (ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ ìš°íšŒ)
- Topical ì‚¬ìš© ê°€ëŠ¥ (ìƒì²˜, ê°ì—¼ ë¶€ìœ„)
- ê´‘ì—­í•™ ì¹˜ë£Œì™€ ê²°í•© ì‹œ ì‹œë„ˆì§€

**ì£¼ìš” ê°œë… 3: Environment-Specific Adaptation (í™˜ê²½ íŠ¹ì´ì  ì ì‘)**

```
Lee ê·¸ë£¹ì˜ Transposon (Tn) sequencing:
â†’ S. aureus ê²Œë†ˆì— ë¬´ì‘ìœ„ Tn ì‚½ì…
â†’ ê° í™˜ê²½ì—ì„œ ìƒì¡´ í•„ìˆ˜ ìœ ì „ì ê·œëª…

í™˜ê²½ 1: ì„¸í¬ ë‚´ (Human blood cell model)
- í•„ìˆ˜ ìœ ì „ì: ì²  íšë“, peptidoglycan í•©ì„±
- íŠ¹ì´ì : Autophagy íšŒí”¼ ë©”ì»¤ë‹ˆì¦˜

í™˜ê²½ 2: í˜ˆë¥˜ (Murine sepsis model)
- í•„ìˆ˜ ìœ ì „ì: Capsule ìƒì„±, ë©´ì—­ íšŒí”¼
- íŠ¹ì´ì : ë³´ì²´(complement) ì €í•­ì„±

í™˜ê²½ 3: ì¡°ì§ (Organ-specific model)
- í: Biofilm í˜•ì„± ìœ ì „ì
- ë¼ˆ: Adhesion ìœ ì „ì
- í”¼ë¶€: Toxin ìƒì„± ìœ ì „ì

â†’ ë°œê²¬: ê²¹ì¹˜ëŠ” ìœ ì „ìë„ ìˆì§€ë§Œ, í™˜ê²½ë³„ë¡œ "ê³ ìœ í•œ í•„ìˆ˜ ìœ ì „ì" ì¡´ì¬
   â†’ ì´ë“¤ì´ ìƒˆë¡œìš´ ì¹˜ë£Œ í‘œì  í›„ë³´
```

**ì˜ë¯¸**:
- ì „ì‹  ê°ì—¼: í˜ˆë¥˜ ìƒì¡´ í‘œì  (capsule, immune evasion)
- êµ­ì†Œ ê°ì—¼: ì¡°ì§ íŠ¹ì´ì  í‘œì  (adhesion, biofilm)
- ë§Œì„± ê°ì—¼: ì„¸í¬ ë‚´ ìƒì¡´ í‘œì  (autophagy, persistence)

---

**[3ì¥: ì‘ìš©ê³¼ ë¯¸ë˜ - ìƒˆë¡œìš´ ì¹˜ë£Œë²•ì˜ ê°€ëŠ¥ì„±]**

**ì‘ìš© 1: ê²°í•µ/NTM ì¹˜ë£Œì˜ ì •ë°€í™”**

```
í˜„ì¬ ë¬¸ì œ:
- Mtbì™€ MACë¥¼ ê°™ì€ regimenìœ¼ë¡œ ì¹˜ë£Œ â†’ íš¨ê³¼ ì œí•œì 
- MAC: M. avium, M. intracellulare, M. abscessus ëª¨ë‘ ë‹¤ë¦„
  â†’ Clarithromycin + Rifampin + Ethambutol (í‘œì¤€)
  â†’ M. abscessusëŠ” ì´ ì¡°í•©ì— ë‚´ì„± (ì¹˜ë£Œ ì‹¤íŒ¨ìœ¨ ë†’ìŒ)

Shin ê·¸ë£¹ì˜ ì œì•ˆ:
â†’ Host-directed therapy (HDT)
  - Mtb: Type I IFN ì°¨ë‹¨ì œ + ê¸°ì¡´ í•­ìƒì œ
    â†’ cGAS-STING ì–µì œì œ, JAK inhibitor ë³‘ìš©

  - MAC: ì§€ë°©ì‚° ëŒ€ì‚¬ ì¡°ì ˆì œ + í•­ìƒì œ
    â†’ PPAR agonist, lipid metabolism modulator

  - Dendritic cell ê¸°ëŠ¥ ê°•í™”
    â†’ TLR agonist, vaccine adjuvant ê°œë°œ

í•µì‹¬ ë°œê²¬:
â†’ Mtb ê°ì—¼ ëª¨ë¸: c-di-GMP (STING agonist) â†’ Th1 â†‘, ìƒì¡´ìœ¨ â†‘
â†’ MAC ê°ì—¼ ëª¨ë¸: Dendritic cell vaccine â†’ í ë³‘ë³€ â†“

â†’ ì„ìƒ ì „ë§: ê¸°ì¡´ í•­ìƒì œ ì¹˜ë£Œ ê¸°ê°„ ë‹¨ì¶• (18ê°œì›” â†’ 6ê°œì›”?)
```

**ì‘ìš© 2: ROS ê¸°ë°˜ í•­ê·  ì¹˜ë£Œì œ**

```
Cho ê·¸ë£¹ì˜ í”Œë«í¼:
â†’ Quinone-based drug repurposing
â†’ Metal-based redirection (Ru, Fe, Cu complexes)

êµ¬ì²´ì  ì˜ˆ:
1. Pseudomonas aeruginosa ë°”ì´ì˜¤í•„ë¦„ ì œê±°
   - Small RNA phage (type IV pilus í‘œì )
   - ROS-generating pharmacophore ê²°í•©
   - ë°”ì´ì˜¤í•„ë¦„ ê°ì—¼ ëª¨ë¸: 97% ì‚¬ë©¸

2. Methicillin-resistant S. aureus (MRSA)
   - Organoruthenium complex
   - MRSA ë°”ì´ì˜¤í•„ë¦„ ì„¸í¬: 3-log reduction
   - In vivo (ë§ˆìš°ìŠ¤ í”¼ë¶€ ê°ì—¼): ë³‘ë³€ í¬ê¸° 80% â†“

3. Designer phage engineering (Cas9 + ROS)
   - Phageë¡œ Cas9 ì „ë‹¬
   - í•„ìˆ˜ ìœ ì „ì íƒ€ê²ŸíŒ… + ROS ìƒì„±
   - S. aureus, P. aeruginosa: ì„ íƒì  ì œê±°

â†’ ì¥ì : ë‚´ì„± ë°œìƒ ì–´ë ¤ì›€ (ROSëŠ” ë¹„íŠ¹ì´ì  ì†ìƒ)
â†’ ë‹¨ì : ì¡°ì§ íŠ¹ì´ì„± í•„ìš” (ì •ìƒ ì„¸í¬ ë³´í˜¸)
â†’ í•´ê²°ì±…: Tissue-targeting ligand ê²°í•© (peptide, antibody)
```

**ì‘ìš© 3: S. aureus ì‹ ê·œ í‘œì  ì•½ë¬¼ ê°œë°œ**

```
Lee ê·¸ë£¹ì˜ ë°œê²¬ì„ ê¸°ë°˜ìœ¼ë¡œ í•œ ì•½ë¬¼ í›„ë³´:

í‘œì  1: 3-Dehydroquinate Dehydratase (DHQD)
- Shikimate pathway íš¨ì†Œ (ì¸ê°„ì— ì—†ìŒ)
- Km = 54 Î¼M, kcat = 48 sâ»Â¹ (ì–µì œì œ ì„¤ê³„ ê°€ëŠ¥)
- ì–µì œ ì‹œ: ë°©í–¥ì¡± ì•„ë¯¸ë…¸ì‚° í•©ì„± â†“ â†’ ì„±ì¥ ì •ì§€

í‘œì  2: Sortase A (SrtA)
- í‘œë©´ ë‹¨ë°±ì§ˆ anchoring íš¨ì†Œ
- Virtual screening + ì‹¤í—˜ ê²€ì¦
  â†’ Lead compound: IC50 = 2.3 Î¼M
- íš¨ê³¼: Adhesion â†“, biofilm â†“, ê°ì—¼ë ¥ â†“

í‘œì  3: Serine Hydrolases
- Virulence factor í™œì„±í™” ê´€ì—¬
- Fluorosulfate covalent inhibitors (2024ë…„ 12ì›” ë°œí‘œ)
- íŠ¹ì´ì : Biofilm í˜•ì„± 70% ì–µì œ

ê¸°ê³„ í•™ìŠµ ìµœì í™”:
â†’ 14,743ê°œ antimicrobial peptide ë°ì´í„°ë¡œ í•™ìŠµ
â†’ CIT-8 peptide ê°œë°œ
  - MRSA persister cells ì œê±°
  - VRSA biofilm ì„¸í¬ ì œê±°
  - ë…ì„±: ë‚®ìŒ (ì„ íƒ ì§€ìˆ˜ > 10)

â†’ ì „ì„ìƒ ë‹¨ê³„: H460 (í ìƒí”¼ ì„¸í¬) ëª¨ë¸ì—ì„œ GFP-S. aureus ì œê±°
   â†’ Intracellular GFP signal 80% â†“ (16ì‹œê°„)
```

**ë¯¸ë˜ ì „ë§**:

```
ë‹¨ê¸° (1-2ë…„):
- ROS ê¸°ë°˜ topical ì œì œ (ìƒì²˜, í™”ìƒ ê°ì—¼)
- Sortase A ì–µì œì œ Phase I ì§„ì… ê°€ëŠ¥ì„±
- Host-directed therapy ì„ìƒì‹œí—˜ (Mtb, MAC)

ì¤‘ê¸° (3-5ë…„):
- í™˜ê²½ íŠ¹ì´ì  í•­ìƒì œ (ì˜ˆ: í˜ˆë¥˜ íŠ¹ì´ì  MRSA ì–µì œì œ)
- Phage-ROS ë³µí•© ì¹˜ë£Œ (biofilm ê°ì—¼)
- AI ê¸°ë°˜ peptide í•­ìƒì œ (ë§ì¶¤í˜• ì„¤ê³„)

ì¥ê¸° (5-10ë…„):
- Precision antibiotics (í™˜ì ê°ì—¼ ë¶€ìœ„ë³„ ìµœì í™”)
- ë©´ì—­ëŒ€ì‚¬ ì¡°ì ˆì œ (MAC, Mtb ë³‘ìš© ìš”ë²•)
- One Health ì ‘ê·¼ (ì¸ê°„-ë™ë¬¼-í™˜ê²½ í†µí•© ë‚´ì„± ê´€ë¦¬)
```

---

## ğŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ğŸ”¹ ë°œí‘œ 1 (13:40-14:05): Two major mycobacterial pathogens in South Korea: From distinct pathogenesis to therapeutic strategies

**ì—°ì‚¬**: Sung Jae Shin, Professor (Yonsei University)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S2-1)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ê²°í•µê· (Mtb)ê³¼ MACëŠ” ë‘˜ ë‹¤ 'í•­ì‚°ê· 'ì´ì§€ë§Œ, ê°ì—¼ ë©”ì»¤ë‹ˆì¦˜ì´ ì™„ì „íˆ ë‹¬ë¼ì„œ ì¹˜ë£Œë²•ë„ ë‹¤ë¥´ê²Œ ê°€ì•¼ í•œë‹¤ëŠ” ì´ì•¼ê¸°"

**ìƒí™©**: í•œêµ­ì˜ í•­ì‚°ê·  ê°ì—¼ ì—­ì„¤

```
ê³¼ê±° (2000ë…„ëŒ€):
- ê²°í•µ(Mtb): ì£¼ìš” ê³µì¤‘ë³´ê±´ ë¬¸ì œ â†’ êµ­ê°€ ê²°í•µ ê´€ë¦¬ ì‚¬ì—…
- NTM(MAC ë“±): ë“œë¬¸ ê¸°íšŒê°ì—¼

í˜„ì¬ (2020ë…„ëŒ€):
- ê²°í•µ: ê´€ë¦¬ ì¤‘ (í•˜ì§€ë§Œ ì—¬ì „íˆ OECD 1ìœ„)
- NTM: ê¸‰ì¦ ì¤‘!
  â†’ 2014: 2.7% â†’ 2019: 4.8%
  â†’ ê³ ë ¹í™”, ë§Œì„± íì§ˆí™˜ í™˜ì ì¦ê°€
  â†’ M. avium complex (MAC)ê°€ 80%
```

**ë¬¸ì œì™€ í•´ê²°**:

- **ë¬¸ì œ 1: ê°™ì€ ì¹˜ë£Œë²• ì‚¬ìš©ì˜ ì˜¤ë¥˜**
  ```
  í˜„ ìƒí™©: Mtbë‚˜ MACë‚˜ ë¹„ìŠ·í•œ í•­ìƒì œ ì¡°í•© ì‚¬ìš©
  â†’ Rifampin, Ethambutol, Macrolide ë“±

  ë¬¸ì œì :
  - MACëŠ” Mtbë³´ë‹¤ ë‚´ì„± ì˜ ìƒê¹€
  - ì¹˜ë£Œ ê¸°ê°„: Mtb 6-9ê°œì›”, MAC 18-24ê°œì›”
  - M. abscessus (MACì˜ ì¼ì¢…): ê±°ì˜ ë¶ˆì¹˜

  â†’ í•´ê²°: ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜ ì°¨ì´ë¥¼ ì´í•´í•´ì•¼ í•¨
  ```

- **ë¬¸ì œ 2: ë©´ì—­ ë°˜ì‘ì´ ë°˜ëŒ€ë¡œ ì‘ìš©**
  ```
  Mtb ê°ì—¼:
  - Type I IFN (ì¸í„°í˜ë¡  ì•ŒíŒŒ/ë² íƒ€) â†‘
  - ì´ê²Œ Th1 ë©´ì—­ ì–µì œ â†’ ì„¸ê·  ìƒì¡´ ë„ì›€
  - Neutrophilì´ ì˜¤íˆë ¤ ì¡°ì§ ì†ìƒ ìœ ë°œ

  MAC ê°ì—¼:
  - ì§€ë°©ì‚° ëŒ€ì‚¬ ë³€í™” (í ì¡°ì§)
  - Dendritic cell ê¸°ëŠ¥ ì•½í™”
  - Macrophage ë‚´ ìƒì¡´ ë©”ì»¤ë‹ˆì¦˜ ë‹¤ë¦„

  â†’ í•´ê²°: ê°ê°ì— ë§ëŠ” ë©´ì—­ ì¡°ì ˆ í•„ìš”
    - Mtb: Type I IFN ì°¨ë‹¨ + Th1 ê°•í™”
    - MAC: Dendritic cell ê°•í™” + ì§€ë°©ì‚° ëŒ€ì‚¬ ì¡°ì ˆ
  ```

**ì˜ë¯¸**:

"ê°œì¸í™” ì¹˜ë£Œ(precision medicine)ëŠ” ì•”ë¿ ì•„ë‹ˆë¼ ê°ì—¼ë³‘ì—ë„ í•„ìš”í•˜ë‹¤.
ê°™ì€ 'í•­ì‚°ê· 'ì´ë¼ë„ Mtbì™€ MACëŠ” ë‹¤ë¥¸ ë³‘ì´ë©°,
ë§ˆìš°ìŠ¤ ëª¨ë¸(C3H/HeJ vs A/J)ì—ì„œ ë°í˜€ì§„ ë©´ì—­í•™ì  ì°¨ì´ë¥¼
ì„ìƒì— ì ìš©í•˜ë©´ ì¹˜ë£Œ ì„±ê³µë¥ ì„ ë†’ì¼ ìˆ˜ ìˆë‹¤."

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**Sung Jae Shinì˜ ì£¼ìš” ì—…ì **:

```
2024-2025: Mtb/MAC ë°±ì‹  ë° ë©´ì—­ì¹˜ë£Œ
- Nature Communications (2025, accepted):
  "Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced
   neutrophilic lung inflammation in tuberculosis"
  â†’ Neutrophilì„ ì¡°ì ˆí•˜ëŠ” Tì„¸í¬ ë°œê²¬
  â†’ íì•” ì¹˜ë£Œ ì¤‘ ê²°í•µ ì•…í™” ë°©ì§€ ì „ëµ

- J Adv Res (2025):
  "Enhanced tuberculosis control via leveraging dendritic cell-mediated
   Th1 responses in preventive and immunotherapeutic vaccine strategies"
  â†’ Dendritic cell ë°±ì‹ ìœ¼ë¡œ Th1 ë°˜ì‘ ê°•í™”
  â†’ ì˜ˆë°© + ì¹˜ë£Œ íš¨ê³¼ ë™ì‹œ ê²€ì¦

2023: MAC ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜
- J Biomed Sci (2023):
  "Protein-Energy Restriction-induced Lipid Metabolism Disruption Causes
   Stabloto-Progressive Disease Shift in Mycobacterium avium-Infected Female Mice"
  â†’ ì§€ë°©ì‚° ëŒ€ì‚¬ê°€ MAC ê°ìˆ˜ì„± ê²°ì •
  â†’ ì—¬ì„± í™˜ìê°€ ë§ì€ ì´ìœ  ì¼ë¶€ ì„¤ëª…

2020-2022: ì°¨ì„¸ëŒ€ ë°±ì‹  ê°œë°œ
- BCG+adjuvanted multivalent subunit vaccine
  â†’ HSP90-Ag85B-MPT64-Rv2190c ì¡°í•©
  â†’ ê¸°ì¡´ BCGë³´ë‹¤ ë³´í˜¸ íš¨ê³¼ ìš°ìˆ˜
```

**í•µì‹¬ ë…¼ë¬¸**:

```
ğŸ“„ Kwon KW, Choi H, Kim E, et al., Shin SJ* (2024)
"BCG+booster vaccination with HSP90-Ag85B-MPT64-Rv2190c multivalent
 subunit vaccine confers durable protection against hypervirulent
 Mtb in mice"
J Adv Res. 9(1):55 (*êµì‹ ì €ì)

í•µì‹¬ ë‚´ìš©:
- HSP90 chaperone + ì£¼ìš” í•­ì› 3ì¢… ê²°í•©
- BCG ë‹¨ë… ëŒ€ë¹„ í ì„¸ê·  ìˆ˜ 2-log ê°ì†Œ
- Th1 ì„¸í¬ + ì¡°ì§ resident memory T cell ìœ ë„
- ë°±ì‹  íš¨ê³¼ ì§€ì†: 150ì¼ ì´ìƒ

ì½ê¸° ì‹œê°„: 45ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (Mtb ë°±ì‹  ê°œë°œì í•„ìˆ˜)
```

```
ğŸ“„ Kim E, Park M, Kwon KW, Shin SJ* (2023)
"Adjunctive beneficial effect of c-di-GMP, a STING agonist,
 in enhancing tuberculosis control via TLR4-adjuvanted tuberculosis subunit vaccine"
J Biomed Sci. 32(1):52

í•µì‹¬ ë‚´ìš©:
- c-di-GMP (STING agonist)ë¥¼ ë°±ì‹  adjuvantë¡œ ì‚¬ìš©
- TLR4 agonistì™€ ë³‘ìš© ì‹œ ì‹œë„ˆì§€
- Type I IFN ì—­ì„¤ í•´ê²°: ì´ˆê¸°ì—ëŠ” í•„ìš”, í›„ê¸°ì—ëŠ” ì–µì œ
- ë§ˆìš°ìŠ¤ ìƒì¡´ìœ¨ 85% â†’ 100%

ì½ê¸° ì‹œê°„: 35ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (ë©´ì—­ ì¡°ì ˆ ì „ëµ)
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**ì£¼ì œ**: í•œêµ­ì˜ Mtbì™€ MAC - ë³„ê°œì˜ ì§ˆë³‘ìœ¼ë¡œ ë‹¤ë¤„ì•¼ í•œë‹¤

**ë‹¤ë£° ë‚´ìš© (ì˜ˆìƒ)**:

```
1. ì—­í•™ ë°ì´í„° (í•œêµ­ íŠ¹ì´ì„±)
   - Mtb: ê°ì†Œ ì¶”ì„¸ì´ë‚˜ OECD ìµœê³  (10ë§Œ ëª…ë‹¹ 40ëª…)
   - NTM: ê¸‰ì¦ (2014 â†’ 2019, 78% ì¦ê°€)
   - MAC ì¢… ë¶„í¬: M. avium 41%, M. intracellulare 38%
   - ì—¬ì„±, ê³ ë ¹ í™˜ì ë¹„ìœ¨ ë†’ìŒ (57.7%, í‰ê·  61.5ì„¸)

2. ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜ ì°¨ì´
   - Mtb: Type I IFN pathway ì•…ìš©
     â†’ Neutrophil ë™ì› â†’ ì¡°ì§ ì†ìƒ
     â†’ STING-IFN axisê°€ í•µì‹¬

   - MAC: ì§€ë°©ì‚° ëŒ€ì‚¬ êµë€
     â†’ Macrophage lipid droplet ì¶•ì 
     â†’ Dendritic cell ê¸°ëŠ¥ ì €í•˜
     â†’ ë©´ì—­ëŒ€ì‚¬ ê²½ë¡œ ì°¨ì´

3. ë§ˆìš°ìŠ¤ ëª¨ë¸ì˜ êµí›ˆ
   - C3H/HeJ (Mtb ë¯¼ê°): Neutrophil/IFN ê¸°ì—¬
     â†’ Neutrophil ì œê±° ì‹œ ë³‘ë³€ â†“
     â†’ Anti-IFN-I antibody íˆ¬ì—¬ ì‹œ ìƒì¡´ìœ¨ â†‘

   - A/J (MAC ë¯¼ê°): ì§€ë°©ì‚° ëŒ€ì‚¬ ê¸°ì—¬
     â†’ í ì§€ë°©ì‚° ìˆ˜ì¹˜ì™€ ë³‘ë³€ ìƒê´€ì„±
     â†’ ëŒ€ì‚¬ ì¡°ì ˆì œ íš¨ê³¼ ìˆìŒ

4. ìƒˆë¡œìš´ ì¹˜ë£Œ ì „ëµ
   - Mtb: Host-directed therapy (HDT)
     â†’ JAK inhibitor (Type I IFN ì°¨ë‹¨)
     â†’ c-di-GMP (STING agonist, ë°±ì‹  adjuvant)
     â†’ Dendritic cell vaccine

   - MAC: ë©´ì—­ëŒ€ì‚¬ ì¡°ì ˆ + í•­ìƒì œ
     â†’ PPAR agonist (ì§€ë°©ì‚° ëŒ€ì‚¬ ì •ìƒí™”)
     â†’ Macrolide + ë©´ì—­ ì¡°ì ˆì œ
     â†’ Dendritic cell ê¸°ëŠ¥ ê°•í™”
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "Mtb â‰  MAC: ì¹˜ë£Œë²•ë„ ë‹¬ë¼ì•¼"
- "Host-directed therapyëŠ” ë¯¸ë˜ê°€ ì•„ë‹Œ í˜„ì¬"
- "ë§ˆìš°ìŠ¤ ëª¨ë¸ì€ ì„ìƒ ì „ëµì˜ ë‚˜ì¹¨ë°˜"

**ë°©ë²•ë¡  (ì˜ˆìƒ)**:
- **In vivo ëª¨ë¸**: C3H/HeJ, A/J ë§ˆìš°ìŠ¤ aerosol ê°ì—¼
- **ë©´ì—­ ë¶„ì„**: Flow cytometry (Th1/Th17/Treg), ELISA (cytokine)
- **ëŒ€ì‚¬ ë¶„ì„**: Lipidomics, transcriptomics (RNA-seq)
- **ì¹˜ë£Œ íš¨ê³¼**: CFU counting, ì¡°ì§ë³‘ë¦¬, ìƒì¡´ ê³¡ì„ 

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì´ ë°œí‘œê°€ ë„ì›€ì´ ë˜ëŠ” ê²½ìš°**:

1. **ê²°í•µ/NTM ì—°êµ¬ì** (ì§ì ‘ ì ìš©)
   - ë§ˆìš°ìŠ¤ ëª¨ë¸ ì„ íƒ ê°€ì´ë“œ (C3H/HeJ vs A/J)
   - Host-directed therapy í›„ë³´ ë¬¼ì§ˆ (JAK inhibitor, STING agonist)
   - ë°±ì‹  adjuvant ì „ëµ (c-di-GMP + TLR4 agonist)

2. **ë©´ì—­í•™ ì—°êµ¬ì** (ë©”ì»¤ë‹ˆì¦˜ ì´í•´)
   - Type I IFNì˜ ì–‘ë©´ì„± (ì´ˆê¸° ë°©ì–´ vs ë§Œì„± ì–µì œ)
   - Dendritic cellì˜ í•­ì› ì œì‹œ ìµœì í™”
   - ë©´ì—­ëŒ€ì‚¬ crosstalk (lipid metabolism â†” immune response)

3. **ì•½ë¬¼ ê°œë°œì** (ì‚°ì—… ì‘ìš©)
   - HDT í›„ë³´ ë¬¼ì§ˆ íƒìƒ‰ (ê¸°ì¡´ ì•½ë¬¼ repurposing ê°€ëŠ¥)
   - ë°±ì‹  adjuvant ì‹œì¥ (STING agonistëŠ” ì•” ë°±ì‹ ì—ë„ ì‚¬ìš©)
   - ì§„ë‹¨ ë§ˆì»¤ ê°œë°œ (Type I IFN signature, lipid profile)

4. **í¬ë‹¥ ì—°êµ¬ì** (ë°©ë²•ë¡  ìŠµë“)
   - ì „ì„ìƒ ëª¨ë¸ ë””ìì¸ (strain ì„ íƒì˜ ì¤‘ìš”ì„±)
   - Multi-omics í†µí•© ë¶„ì„ (transcriptomics + lipidomics + immunology)
   - ê¸°ì´ˆ-ì„ìƒ ì—°ê³„ ì—°êµ¬ ì„¤ê³„

**ì‘ìš© ê°€ëŠ¥ì„±**:

- **ì„ìƒì‹œí—˜ ì„¤ê³„**: Mtb/MAC í™˜ìì—ì„œ Type I IFN ì°¨ë‹¨ì œ ë³‘ìš© (ruxolitinib ë“±)
- **ë°”ì´ì˜¤ë§ˆì»¤ ê°œë°œ**: í˜ˆì•¡ ë‚´ ì§€ë°©ì‚° profileë¡œ MAC ê°ìˆ˜ì„± ì˜ˆì¸¡
- **ë°±ì‹  í”Œë«í¼**: Dendritic cell vaccine + adjuvant (c-di-GMP)

**ê¸°ìˆ  ì´ì „ ê°€ëŠ¥ì„±**:

- **ë©´ì—­ ë¶„ì„ í”„ë¡œí† ì½œ**: Flow panel ë””ìì¸ (Th1/Th17/Treg ë™ì‹œ ë¶„ì„)
- **ëŒ€ì‚¬ ë¶„ì„ í”Œë«í¼**: Lipidomics workflow (í ì¡°ì§, í˜ˆì²­)
- **ë§ˆìš°ìŠ¤ ê°ì—¼ ëª¨ë¸**: Aerosol infection setup (BSL-3 facility)

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

1. **Type I IFN ì°¨ë‹¨ ì‹œì ì€ ì–¸ì œê°€ ìµœì ì¸ê°€?**
   - **ë°°ê²½**: ì´ˆê¸°ì—ëŠ” ë°©ì–´ íš¨ê³¼ ìˆì§€ë§Œ, ë§Œì„±ê¸°ì—ëŠ” ì–µì œ íš¨ê³¼
   - **ì˜ë„**: ì„ìƒ ì ìš© ì‹œ íˆ¬ì—¬ ì‹œì  ê²°ì •ì— ì¤‘ìš”
   - **ì˜ˆìƒ ë‹µë³€**: ê°ì—¼ í›„ 2-4ì£¼ (ë§Œì„±ê¸° ì§„ì… ì‹œì )

2. **A/J ë§ˆìš°ìŠ¤ì˜ ì§€ë°©ì‚° ëŒ€ì‚¬ ë³€í™”ê°€ ì¸ê°„ì—ì„œë„ ì¬í˜„ë˜ëŠ”ê°€?**
   - **ë°°ê²½**: MAC í™˜ìì˜ ì—¬ì„± ë¹„ìœ¨ì´ ë†’ì€ë°, ì§€ë°©ëŒ€ì‚¬ì™€ ê´€ë ¨?
   - **ì˜ë„**: ë§ˆìš°ìŠ¤ ëª¨ë¸ì˜ ì„ìƒ relevance í™•ì¸

3. **Dendritic cell vaccineì˜ í•­ì›ì€ ì–´ë–»ê²Œ ì„ íƒí–ˆëŠ”ê°€?**
   - **ë°°ê²½**: Mtb í•­ì› 3,000ê°œ ì´ìƒ, MAC í•­ì›ë„ ìˆ˜ì²œ ê°œ
   - **ì˜ë„**: ë°±ì‹  ê°œë°œ ì‹œ í•­ì› ì„ íƒ ì „ëµ ì´í•´

**ê¸°ìˆ ì  ì§ˆë¬¸**:

1. **c-di-GMPì˜ delivery ë°©ë²•ì€?** (adjuvantë¡œ ì‚¬ìš© ì‹œ formulation)
2. **Lipidomics ë¶„ì„ í”Œë«í¼ì€?** (LC-MS/MS? GC-MS? ì „ì²˜ë¦¬ ë°©ë²•)
3. **Aerosol ê°ì—¼ ìš©ëŸ‰ì€ ì–´ë–»ê²Œ í‘œì¤€í™”í–ˆëŠ”ê°€?** (CFU ê· ì¼ì„± í™•ë³´)

**ì‘ìš© ê´€ë ¨**:

1. **JAK inhibitor (ruxolitinib ë“±)ë¥¼ Mtb í™˜ìì—ê²Œ ì„ìƒì‹œí—˜ ê³„íšì´ ìˆëŠ”ê°€?**
2. **MAC ì¹˜ë£Œì— PPAR agonist (pioglitazone ë“±) ë³‘ìš© íš¨ê³¼ëŠ”?**
3. **í•œêµ­ì—ì„œ NTM ê¸‰ì¦ ì›ì¸ì´ í™˜ê²½ ìš”ì¸ì¸ê°€? (ìˆ˜ë—ë¬¼, í† ì–‘)**

**ë¹„íŒì  ì§ˆë¬¸** (ì‹ ì¤‘íˆ):

1. **ë§ˆìš°ìŠ¤ ëª¨ë¸ì˜ í•œê³„ëŠ”?** (ì¸ê°„ì˜ ìœ¡ì•„ì¢… í˜•ì„± ì¬í˜„ ì–´ë ¤ì›€)
   - ê°€ëŠ¥í•œ í›„ì† ì§ˆë¬¸: "Non-human primate ëª¨ë¸ ê³„íšì€?"

2. **Type I IFN ì°¨ë‹¨ì´ ë‹¤ë¥¸ ê°ì—¼ ìœ„í—˜ì„ ë†’ì´ì§€ ì•ŠëŠ”ê°€?**
   - ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ (COVID-19, influenza) ì·¨ì•½ì„± ì¦ê°€ ìš°ë ¤

---

### ğŸ”¹ ë°œí‘œ 2 (14:05-14:30): Antibacterial strategies based on the pharmacophores generating reactive oxygen species

**ì—°ì‚¬**: You-Hee Cho, Professor (CHA University)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S2-2)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ì„¸ê· ì„ ì£½ì´ëŠ” 'í™œì„±ì‚°ì†Œ(ROS)'ë¥¼ ì•½ë¬¼ë¡œ ë§Œë“¤ì–´ì„œ, ì„¸ê· ë§Œ ì„ íƒì ìœ¼ë¡œ í„°ëœ¨ë¦¬ëŠ” ë°©ë²•"

**ìƒí™©**: í•­ìƒì œ ë‚´ì„±ì˜ ë”œë ˆë§ˆ

```
ë¬¸ì œ:
- ìƒˆ í•­ìƒì œ ê°œë°œí•´ë„ 2-3ë…„ ë‚´ ë‚´ì„± ì¶œí˜„
- MDR (ë‹¤ì œë‚´ì„±), XDR (ê´‘ë²”ìœ„ë‚´ì„±) ì¦ê°€
- ì‹ ì•½ ê°œë°œ ë¹„ìš©: í‰ê·  $1B, ê¸°ê°„: 10-15ë…„

ê¸°ì¡´ ì ‘ê·¼ë²•ì˜ í•œê³„:
- íŠ¹ì • í‘œì  (ë¦¬ë³´ì†œ, DNA gyrase, ì„¸í¬ë²½ í•©ì„± íš¨ì†Œ)
  â†’ ëŒì—°ë³€ì´ë¡œ ì‰½ê²Œ ë‚´ì„± íšë“

í•„ìš”í•œ ê²ƒ:
- ë‚´ì„±ì´ ìƒê¸°ê¸° ì–´ë ¤ìš´ ë©”ì»¤ë‹ˆì¦˜
- ê´‘ë²”ìœ„ íš¨ê³¼ (broad-spectrum)
- ì •ìƒ ì„¸í¬ì—ëŠ” ë…ì„± ë‚®ìŒ
```

**ë¬¸ì œì™€ í•´ê²°**:

- **ë¬¸ì œ: ROSëŠ” ì–‘ë‚ ì˜ ê²€**
  ```
  ROSì˜ ì—­í• :
  - ë©´ì—­ ì„¸í¬: ì„¸ê·  ì£½ì´ëŠ” ë¬´ê¸° (phagocyte NADPH oxidase)
  - í•­ìƒì œ: ë§ì€ í•­ìƒì œê°€ ë¶€ìˆ˜ì ìœ¼ë¡œ ROS ìƒì„±

  ë¬¸ì œì :
  - ë¹„ì„ íƒì  (ì •ìƒ ì„¸í¬ë„ ì†ìƒ)
  - ì¡°ì§ ì—¼ì¦, ì‚°í™” ìŠ¤íŠ¸ë ˆìŠ¤

  â†’ í•´ê²°: "ì„ íƒì  ROS ìƒì„±" í•„ìš”
    â†’ ì„¸ê·  ì•ˆì—ì„œë§Œ ROS ë§Œë“¤ê¸°
    â†’ ì •ìƒ ì„¸í¬ëŠ” ë¯¸í† ì½˜ë“œë¦¬ì•„ì—ì„œ ROS ê²©ë¦¬
  ```

- **í•´ê²°: Pharmacophore (ì•½ë¦¬í™œì„±ê¸°) ì„¤ê³„**
  ```
  Pharmacophoreë€?
  â†’ ì•½ë¬¼ ë¶„ì ì¤‘ "ì‹¤ì œ íš¨ê³¼ ë‚´ëŠ” ë¶€ë¶„"
  â†’ ì˜ˆ: Quinone ê³¨ê²©, Metal complex ë“±

  Cho ê·¸ë£¹ì˜ ì „ëµ:
  1. Quinone-based compounds
     - ì„¸í¬ ë‚´ O2 â†’ O2â€¢âˆ’ (superoxide) í™˜ì›
     - ì„¸ê· ì˜ í•­ì‚°í™” ì‹œìŠ¤í…œ í¬í™”
     - ê²°ê³¼: ROS ì¶•ì  â†’ ì„¸í¬ ì‚¬ë©¸

  2. Metal-based redirection
     - Organoruthenium complex
     - Schiff-base ligand (ì„ íƒì„± ë¶€ì—¬)
     - Transfer hydrogenation: O2 â†’ H2O2
     - ê·¸ëŒì–‘ì„±ê· ì—ë§Œ íš¨ê³¼ (ì„¸í¬ë²½ íˆ¬ê³¼)

  3. Phage + ROS ê²°í•©
     - Designer phageë¡œ Cas9 ì „ë‹¬
     - Cas9ê°€ í•„ìˆ˜ ìœ ì „ì ì ˆë‹¨
     - ë™ì‹œì— ROS ìƒì„± â†’ ì´ì¤‘ íƒ€ê²©
  ```

**ì˜ë¯¸**:

"ROSëŠ” 'ë…'ì´ ì•„ë‹ˆë¼ 'ì•½'ì´ ë  ìˆ˜ ìˆë‹¤.
í•µì‹¬ì€ 'ì–´ë””ì„œ ë§Œë“œëŠëƒ'ì´ë‹¤.
Pharmacophore ì„¤ê³„ë¡œ ì„¸ê·  ë‚´ë¶€ì—ì„œë§Œ ROSë¥¼ ìƒì„±í•˜ë©´,
ë‚´ì„± ì—†ì´, ê´‘ë²”ìœ„í•˜ê²Œ, ì•ˆì „í•˜ê²Œ ì„¸ê· ì„ ì œê±°í•  ìˆ˜ ìˆë‹¤."

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**You-Hee Choì˜ ì£¼ìš” ì—…ì **:

```
2024-2025: ROS-mediated antibacterial therapy
- Int J Mol Sci (2024):
  "Reactive Oxygen Species (ROS)-Mediated Antibacterial Oxidative Therapies:
   Available Methods to Generate ROS and a Novel Option Proposal"
  â†’ ROS ìƒì„± ë°©ë²• ì´ì •ë¦¬ (photodynamic, plasma, chemical)
  â†’ ì„ìƒ ìŠ¹ì¸ëœ topical ROS ì¹˜ë£Œ (ìƒì²˜, ê¶¤ì–‘)

- J Virol (2025):
  "Pilin regions that select for the small RNA phages in Pseudomonas aeruginosa
   type IV pilus"
  â†’ Type IV pilus íŠ¹ì´ì  RNA phage ê°œë°œ
  â†’ ROS-generating moduleê³¼ ê²°í•© ê°€ëŠ¥ì„±

2022-2023: Pseudomonas aeruginosa ì œì–´
- J Microbiol (2024):
  "Use of Cas9 targeting and Red recombination for designer phage engineering"
  â†’ Phage genomeì— Cas9 ì‚½ì…
  â†’ í•„ìˆ˜ ìœ ì „ì íƒ€ê²ŸíŒ… â†’ ì„¸ê·  íŠ¹ì´ì  ì œê±°

2020-2021: Metal-based antibacterials
- JACS Au (2021):
  "Targeted Antibacterial Strategy Based on Reactive Oxygen Species
   Generated from Dioxygen Reduction Using an Organoruthenium Complex"
  â†’ 480ê°œ organoruthenium complex ë¼ì´ë¸ŒëŸ¬ë¦¬
  â†’ Lead compound: ê·¸ëŒì–‘ì„±ê·  íŠ¹ì´ì 
  â†’ Transfer hydrogenation ë©”ì»¤ë‹ˆì¦˜ ê·œëª…
```

**í•µì‹¬ ë…¼ë¬¸**:

```
ğŸ“„ You-Hee Cho*, et al. (2024)
"Reactive Oxygen Species (ROS)-Mediated Antibacterial Oxidative Therapies"
Int J Mol Sci. 25(13):7182

í•µì‹¬ ë‚´ìš©:
- ROS ìƒì„± ë°©ë²• 6ê°€ì§€ ë¹„êµ:
  1. Bactericidal antibiotics (fluoroquinolone, aminoglycoside)
  2. Photodynamic therapy (photosensitizer + light)
  3. TiO2 photocatalysis
  4. Cold atmospheric plasma
  5. Medicinal honey (H2O2 + other factors)
  6. Chemical pharmacophores (quinones, metal complexes)

- ê° ë°©ë²•ì˜ ì¥ë‹¨ì , ì„ìƒ í˜„í™©
- Novel option: ì„¸í¬ íˆ¬ê³¼ì„± ROS generator

ì½ê¸° ì‹œê°„: 40ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (ROS ì¹˜ë£Œ ì…ë¬¸ì í•„ìˆ˜)
```

```
ğŸ“„ Cho Y-H*, Bae H-W, et al. (2021)
"Targeted Antibacterial Strategy Based on ROS Generated from
 Dioxygen Reduction Using an Organoruthenium Complex"
JACS Au. 1(8):1171-1181

í•µì‹¬ ë‚´ìš©:
- Organoruthenium(II)-Schiff base complex í•©ì„±
- Mechanism: [Ru]-H + O2 â†’ [Ru]+ + H2O2
  â†’ Transfer hydrogenation reaction
- ì„ íƒì„±: ê·¸ëŒì–‘ì„±ê·  (S. aureus, MRSA) > ê·¸ëŒìŒì„±ê· 
- In vitro: MRSA biofilm 3-log reduction
- Cytotoxicity: ì¸ê°„ ì„¸í¬ IC50 > 100 Î¼M (ì¹˜ë£Œ ìš©ëŸ‰ì˜ 10ë°°)

ì½ê¸° ì‹œê°„: 50ë¶„ (ìœ ê¸°ê¸ˆì†í™”í•™ ë°°ê²½ í•„ìš”)
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (metal-based drug ê°œë°œì)
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**ì£¼ì œ**: ROSë¥¼ í™œìš©í•œ ì°¨ì„¸ëŒ€ í•­ê·  ì „ëµ

**ë‹¤ë£° ë‚´ìš© (ì˜ˆìƒ)**:

```
1. ROS ìƒë¬¼í•™ ê¸°ì´ˆ
   - ROS ì¢…ë¥˜: O2â€¢âˆ’, H2O2, â€¢OH, 1O2
   - ìƒì„± ê²½ë¡œ: NADPH oxidase, mitochondria, ì•½ë¬¼
   - ì„¸ê· ì˜ ROS ë°©ì–´: SOD (O2â€¢âˆ’ â†’ H2O2), Catalase (H2O2 â†’ H2O + O2)
   - í•­ìƒì œì˜ ROS ê¸°ì—¬: Fluoroquinolone, Aminoglycoside (30-40%)

2. ê¸°ì¡´ ROS ì¹˜ë£Œë²•ì˜ í•œê³„
   - Photodynamic therapy (PDT):
     â†’ Photosensitizer + ë¹› â†’ 1O2 ìƒì„±
     â†’ ì¥ì : ê°•ë ¥, ë‚´ì„± ì—†ìŒ
     â†’ ë‹¨ì : ì¡°ì§ ê¹Šì´ ì œí•œ (ë¹› íˆ¬ê³¼), ì¥ë¹„ í•„ìš”

   - Cold plasma:
     â†’ ROS + reactive nitrogen species (RNS) ìƒì„±
     â†’ ì¥ì : ë¹ ë¥¸ ì‚´ê· 
     â†’ ë‹¨ì : í‘œë©´ë§Œ ê°€ëŠ¥, ì¡°ì§ ì†ìƒ ìœ„í—˜

   - Honey:
     â†’ H2O2 + methylglyoxal + defensin-1
     â†’ ì¥ì : ì²œì—°, ìƒì²˜ ì¹˜ìœ  ì´‰ì§„
     â†’ ë‹¨ì : íš¨ê³¼ ì˜ˆì¸¡ ì–´ë ¤ì›€, í‘œì¤€í™” ë¬¸ì œ

3. Pharmacophore ê¸°ë°˜ ROS ìƒì„±
   - Quinone redox cycling:
     â†’ Quinone + NAD(P)H â†’ Semiquinone
     â†’ Semiquinone + O2 â†’ Quinone + O2â€¢âˆ’
     â†’ ì„¸ê·  NAD(P)H ê³ ê°ˆ + ROS ì¶•ì 

   - Metal complex (Ru, Fe, Cu):
     â†’ [M(II)]-ligand + O2 â†’ [M(III)] + O2â€¢âˆ’/H2O2
     â†’ Ligandë¡œ ì„ íƒì„± ì¡°ì ˆ
     â†’ ì˜ˆ: Schiff-base (aromatic amine + aldehyde)

   - Design principles:
     â†’ ì„¸ê·  ì„¸í¬ë²½ íˆ¬ê³¼ì„±
     â†’ ì„¸í¬ ë‚´ í™˜ì› í™˜ê²½ì—ì„œ í™œì„±í™”
     â†’ ì •ìƒ ì„¸í¬ëŠ” ë¯¸í† ì½˜ë“œë¦¬ì•„ì—ì„œ ê²©ë¦¬

4. ì‹¤ì œ ì‘ìš© ì‚¬ë¡€
   - MRSA biofilm ì œê±°:
     â†’ Organoruthenium complex (10 Î¼M)
     â†’ Biofilm ì„¸í¬: 99.9% ì‚¬ë©¸ (24h)
     â†’ Mechanism: H2O2 ì¶•ì  (catalase í¬í™”)

   - P. aeruginosa phage therapy:
     â†’ Small RNA phage (type IV pilus íŠ¹ì´ì )
     â†’ Phage + quinone ë³‘ìš©
     â†’ Biofilm ê°ì—¼ ëª¨ë¸: 97% ì œê±°

   - Designer phage (Cas9 + ROS):
     â†’ Phageë¡œ Cas9 + ROS generator ì „ë‹¬
     â†’ Essential gene íƒ€ê²ŸíŒ… + ROS ìƒì„±
     â†’ S. aureus: ì„ íƒì  ì œê±° (E. coli ì˜í–¥ ì—†ìŒ)
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "ROSëŠ” ë‚´ì„± ì—†ëŠ” í•­ê·  ë©”ì»¤ë‹ˆì¦˜"
- "Pharmacophore ì„¤ê³„ë¡œ ì„ íƒì„± í™•ë³´"
- "Phage + ROS ê²°í•©ì€ ë¯¸ë˜ ì¹˜ë£Œ ì˜µì…˜"

**ë°©ë²•ë¡  (ì˜ˆìƒ)**:
- **í™”í•™ í•©ì„±**: Organoruthenium complex (Schiff-base ligand)
- **ROS ì¸¡ì •**: DCFH-DA assay, DHE staining, H2O2 probe
- **Biofilm assay**: Crystal violet staining, confocal microscopy (live/dead)
- **Phage engineering**: CRISPR-Cas9, Red recombination

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì´ ë°œí‘œê°€ ë„ì›€ì´ ë˜ëŠ” ê²½ìš°**:

1. **í•­ìƒì œ ê°œë°œì** (ì‹ ì•½ í›„ë³´ ë°œêµ´)
   - Quinone, metal complex scaffold í™œìš©
   - Redox cycling ë©”ì»¤ë‹ˆì¦˜ ì´í•´
   - Structure-activity relationship (SAR) ì—°êµ¬

2. **ê°ì—¼ ì¹˜ë£Œ ì—°êµ¬ì** (ì„ìƒ ì‘ìš©)
   - Topical ê°ì—¼ (ìƒì²˜, í™”ìƒ, ë‹¹ë‡¨ë°œ ê¶¤ì–‘)
   - Catheter-related infection (biofilm)
   - Phage therapyì™€ ë³‘ìš© ì „ëµ

3. **ë¬´ê¸°í™”í•™/ê¸ˆì†ì•½ë¬¼ ì—°êµ¬ì** (ê¸°ì´ˆ ë©”ì»¤ë‹ˆì¦˜)
   - Ruthenium, Iron, Copper complexì˜ ìƒë¬¼í•™ì  í™œì„±
   - Ligand ì„¤ê³„ë¡œ ì„ íƒì„± ì¡°ì ˆ
   - Transfer hydrogenation reaction in vivo

4. **í¬ë‹¥ ì—°êµ¬ì** (í•™ì œê°„ ì—°êµ¬)
   - í™”í•™ + ë¯¸ìƒë¬¼í•™ ìœµí•©
   - Metal-based drug ì„¤ê³„ ë°©ë²•ë¡ 
   - High-throughput screening (480 compounds)

**ì‘ìš© ê°€ëŠ¥ì„±**:

- **Topical ì œì œ ê°œë°œ**: ìƒì²˜ ì¹˜ë£Œìš© Ru complex gel/cream
- **Catheter coating**: ROS-generating material (biofilm ë°©ì§€)
- **Phage cocktail**: Phage + ROS generator ë³µí•© ì¹˜ë£Œ

**ê¸°ìˆ  ì´ì „ ê°€ëŠ¥ì„±**:

- **Compound library**: Organoruthenium complex 480ì¢… (ë¼ì´ì„ ì‹± ê°€ëŠ¥)
- **ROS assay platform**: High-throughput screening setup
- **Designer phage ê¸°ìˆ **: Cas9-armed phage ì œì‘ protocol

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

1. **Ruthenium complexê°€ ê·¸ëŒìŒì„±ê· ì— ëœ íš¨ê³¼ì ì¸ ì´ìœ ëŠ”?**
   - **ë°°ê²½**: ì™¸ë§‰(outer membrane)ì´ íˆ¬ê³¼ ì¥ë²½
   - **ì˜ë„**: Gram-negative íŠ¹ì´ì  ligand ì„¤ê³„ íŒíŠ¸

2. **ì„¸ê· ì˜ catalaseê°€ H2O2ë¥¼ ë¶„í•´í•˜ëŠ”ë°, ì–´ë–»ê²Œ ROSê°€ ì¶•ì ë˜ëŠ”ê°€?**
   - **ë°°ê²½**: Catalase ê³¼í¬í™”(saturation) ë©”ì»¤ë‹ˆì¦˜
   - **ì˜ˆìƒ ë‹µë³€**: Ru complexì˜ H2O2 ìƒì„± ì†ë„ > catalase ë¶„í•´ ì†ë„

3. **Designer phageì˜ Cas9ê°€ ì„¸ê·  genomic DNAë¥¼ ìë¥´ë©´, phage DNAë„ ì˜í–¥ ë°›ì§€ ì•ŠëŠ”ê°€?**
   - **ë°°ê²½**: Cas9 íŠ¹ì´ì„±, PAM sequence ì„ íƒ

**ê¸°ìˆ ì  ì§ˆë¬¸**:

1. **Organoruthenium complexì˜ ì•½ë¬¼ë™íƒœí•™(PK)ì€?** (ìƒì²´ ë‚´ ì•ˆì •ì„±, ë°˜ê°ê¸°)
2. **DCFH-DA assayë¡œ ROS ì¸¡ì • ì‹œ ìœ„ì–‘ì„± ë¬¸ì œëŠ”?** (ë‹¤ë¥¸ ROS probe ë³‘ìš©?)
3. **Phage + ROS ë³‘ìš© ì‹œ ìµœì  ë¹„ìœ¨ì€?** (MOIì™€ ROS ë†ë„)

**ì‘ìš© ê´€ë ¨**:

1. **ì„ìƒì‹œí—˜ ê³„íšì´ ìˆëŠ”ê°€?** (topical formulation, Phase I/II)
2. **FDA ìŠ¹ì¸ ê²½ë¡œëŠ”?** (medical device vs. new drug)
3. **íŠ¹í—ˆ ìƒí™©ì€?** (Ru complex, designer phage)

**ë¹„íŒì  ì§ˆë¬¸** (ì‹ ì¤‘íˆ):

1. **Rutheniumì˜ ì²´ë‚´ ì¶•ì  ë¬¸ì œëŠ”?** (ì¤‘ê¸ˆì† ë…ì„± ìš°ë ¤)
   - ê°€ëŠ¥í•œ í›„ì† ì§ˆë¬¸: "ë°°ì„¤ ê²½ë¡œ ì—°êµ¬ ê²°ê³¼ëŠ”?"

2. **Phage therapyì˜ ê·œì œ ì¥ë²½ì€?** (í•œêµ­, ë¯¸êµ­, EUì—ì„œ ìŠ¹ì¸ ì–´ë ¤ì›€)

---

### ğŸ”¹ ë°œí‘œ 3 (14:30-14:55): Discovery and functional characterization of novel antibiotic targets in Staphylococcus aureus

**ì—°ì‚¬**: Wonsik Lee, Associate Professor (Sungkyunkwan University)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S2-3)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "í™©ìƒ‰í¬ë„ìƒêµ¬ê· (S. aureus)ì´ 'ì–´ë””ì— ìˆëŠëƒ'ì— ë”°ë¼ ë‹¤ë¥¸ ìƒì¡´ ì „ëµì„ ì“°ëŠ”ë°, ê·¸ í•µì‹¬ ìœ ì „ìë“¤ì„ ì°¾ì•„ì„œ ìƒˆë¡œìš´ í•­ìƒì œ í‘œì ìœ¼ë¡œ ë§Œë“¤ìëŠ” ì´ì•¼ê¸°"

**ìƒí™©**: S. aureusì˜ "ì¹´ë©œë ˆì˜¨" ì „ëµ

```
S. aureusì˜ ë‹¤ì¬ë‹¤ëŠ¥í•¨:
- í”¼ë¶€ í‘œë©´: 30%ì˜ ì‚¬ëŒì´ ë³´ê·  (ë¬´ì¦ìƒ)
- ìƒì²˜: í™”ë†ì„± ê°ì—¼
- í˜ˆë¥˜: íŒ¨í˜ˆì¦ (ì‚¬ë§ë¥  20-30%)
- ë¼ˆ: ê³¨ìˆ˜ì—¼ (ë§Œì„±, ì¬ë°œ ì˜í•¨)
- í: íë ´ (ì¸í”Œë£¨ì—”ì í›„ 2ì°¨ ê°ì—¼)
- ì‹¬ì¥: ì‹¬ë‚´ë§‰ì—¼ (íŒë§‰ ì†ìƒ)

ë¬¸ì œ:
â†’ í•œ ê°€ì§€ í•­ìƒì œë¡œ ëª¨ë“  ë¶€ìœ„ ì¹˜ë£Œ ì–´ë ¤ì›€
â†’ ì˜ˆ: Vancomycin (í˜ˆë¥˜ íš¨ê³¼ ì¢‹ìŒ) vs. Rifampin (ì¡°ì§ ì¹¨íˆ¬ ì¢‹ìŒ)
â†’ ì™œ? ê° í™˜ê²½ì—ì„œ S. aureusì˜ ìƒë¦¬ê°€ ë‹¤ë¥´ê¸° ë•Œë¬¸
```

**ë¬¸ì œì™€ í•´ê²°**:

- **ë¬¸ì œ: í™˜ê²½ë§ˆë‹¤ ë‹¤ë¥¸ í•„ìˆ˜ ìœ ì „ì**
  ```
  ì „í†µì  í•­ìƒì œ ê°œë°œ:
  â†’ In vitro (ë°°ì–‘ì•¡)ì—ì„œ ì„±ì¥ ì–µì œ ë¬¼ì§ˆ ì°¾ê¸°
  â†’ ë¬¸ì œ: ë°°ì–‘ì•¡ â‰  ì¸ì²´ í™˜ê²½
    - ì˜ì–‘ë¶„: í’ë¶€ vs. ì œí•œì 
    - pH: ì¤‘ì„± vs. ì‚°ì„± (phagosome)
    - ì‚°ì†Œ: ì¶©ë¶„ vs. ì €ì‚°ì†Œ (biofilm ë‚´ë¶€)

  â†’ ê²°ê³¼: In vitroì—ì„œ íš¨ê³¼ ìˆì–´ë„ in vivoì—ì„œ ì‹¤íŒ¨
  ```

- **í•´ê²°: Transposon (Tn) sequencingìœ¼ë¡œ í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ì ì°¾ê¸°**
  ```
  Tn sequencingì´ë€?
  â†’ S. aureus ìœ ì „ì²´ì— ë¬´ì‘ìœ„ë¡œ Transposon ì‚½ì…
  â†’ ê° ìœ ì „ìê°€ ë§ê°€ì§„ mutant ìˆ˜ì²œ ê°œ ìƒì„±
  â†’ íŠ¹ì • í™˜ê²½(í˜ˆë¥˜, ì„¸í¬ ë‚´, ì¡°ì§)ì—ì„œ í‚¤ì›€
  â†’ ì‚´ì•„ë‚¨ì§€ ëª»í•œ mutant = í•„ìˆ˜ ìœ ì „ì ë§ê°€ì§„ ê²ƒ
  â†’ Sequencingìœ¼ë¡œ ì–´ë–¤ ìœ ì „ìì¸ì§€ íŒŒì•…

  Lee ê·¸ë£¹ì˜ ë°œê²¬:
  1. ì„¸í¬ ë‚´ (macrophage):
     - ì²  íšë“ ìœ ì „ì (siderophore)
     - Peptidoglycan í•©ì„± ìœ ì „ì
     - Autophagy íšŒí”¼ ê´€ë ¨ ìœ ì „ì

  2. í˜ˆë¥˜ (sepsis model):
     - Capsule ìƒì„± ìœ ì „ì (ë©´ì—­ íšŒí”¼)
     - ë³´ì²´(complement) ì €í•­ì„± ìœ ì „ì
     - Coagulase (í˜ˆì•¡ ì‘ê³ )

  3. ì¡°ì§ (organ-specific):
     - Biofilm í˜•ì„± ìœ ì „ì (í, ì¹´í…Œí„°)
     - Adhesion ìœ ì „ì (ë¼ˆ, ì‹¬ì¥)
     - Toxin ìƒì„± ìœ ì „ì (í”¼ë¶€)

  â†’ í•µì‹¬: ê²¹ì¹˜ëŠ” ìœ ì „ìë„ ìˆì§€ë§Œ, "í™˜ê²½ íŠ¹ì´ì " ìœ ì „ìê°€ ì¡´ì¬
    â†’ ì´ë“¤ì„ í‘œì ìœ¼ë¡œ í•˜ë©´ "ë¶€ìœ„ë³„ ë§ì¶¤ í•­ìƒì œ" ê°€ëŠ¥
  ```

**ì˜ë¯¸**:

"S. aureusë¥¼ ì¡ìœ¼ë ¤ë©´, 'S. aureusê°€ ì–´ë”” ìˆëŠ”ì§€'ë¥¼ ë¨¼ì € ë¬¼ì–´ì•¼ í•œë‹¤.
í˜ˆë¥˜ ê°ì—¼ì—ëŠ” í˜ˆë¥˜ ìƒì¡´ í•„ìˆ˜ ìœ ì „ìë¥¼,
ë¼ˆ ê°ì—¼ì—ëŠ” ë¼ˆ ì¹¨íˆ¬ í•„ìˆ˜ ìœ ì „ìë¥¼ ë§‰ì•„ì•¼ í•œë‹¤.
Precision antibioticì˜ ì‹œëŒ€ê°€ ì˜¨ë‹¤."

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**Wonsik Leeì˜ ì£¼ìš” ì—…ì **:

```
2024-2025: S. aureus í™˜ê²½ë³„ ì ì‘ ë©”ì»¤ë‹ˆì¦˜
- Nature Communications (2025, Jul):
  "Environmental fitness of different host niches shape the survival fitness
   of Staphylococcus aureus"
  â†’ Tn-seqë¡œ 9ê°œ ê°ì—¼ í™˜ê²½ ë¹„êµ
  â†’ ì„¸í¬ ë‚´, í˜ˆë¥˜, ì¡°ì§ë³„ í•„ìˆ˜ ìœ ì „ì map ì™„ì„±
  â†’ í™˜ê²½ íŠ¹ì´ì  ìœ ì „ì vs. ê³µí†µ í•„ìˆ˜ ìœ ì „ì êµ¬ë¶„

- Advanced Sciences (2024, Jul):
  "Reducing Peptidoglycan Crosslinking by Chemical Modulator Reverts
   Î²-lactam Resistance in Methicillin-Resistant S. aureus"
  â†’ PG crosslinking ì–µì œì œ + Î²-lactam ë³‘ìš©
  â†’ MRSA ë‚´ì„± ê·¹ë³µ (Î²-lactam ì¬í™œìš©)

2023: S. aureus ì‹ ê·œ í‘œì  ê²€ì¦
- ACS Central Science (2025, Sep):
  "Reshaping Tumor-Lymph Node Immune Axis via Targeted Lymphatic
   Delivery of Dual-Functional Immune Modulator"
  â†’ Tumor modelì´ì§€ë§Œ, immune modulator ê¸°ìˆ ì€ ê°ì—¼ì—ë„ ì‘ìš© ê°€ëŠ¥

- J Am Chem Soc (2025, May):
  "Erythromycin Stress Upregulates Antagonogenic Metabolites in the
   Gut Bacterium Aneurotruncus colihominis"
  â†’ ì¥ë‚´ ë¯¸ìƒë¬¼ ì—°êµ¬ì´ì§€ë§Œ, Tn-seq ë°©ë²•ë¡  ë™ì¼
```

**í•µì‹¬ ë…¼ë¬¸**:

```
ğŸ“„ Chang J, et al., Lee W* (2025)
"Environmental fitness of different host niches shape the survival fitness
 of Staphylococcus aureus"
Nature Communications. Jul 28;16(1):6928

í•µì‹¬ ë‚´ìš©:
- Tn-seqì„ 9ê°œ ëª¨ë¸ì— ì ìš©:
  1. Human blood cell (H460 ì„¸í¬ì£¼)
  2. Murine sepsis (ì •ë§¥ ì£¼ì‚¬)
  3. Lung organoid (í ìƒí”¼)
  4. Bone organoid (osteoblast)
  5. Skin infection (í”¼í•˜ ì£¼ì‚¬)
  + 4ê°œ ì¶”ê°€ ëª¨ë¸

- ë°œê²¬:
  â†’ ê³µí†µ í•„ìˆ˜ ìœ ì „ì: 287ê°œ (ëŒ€ì‚¬, PG í•©ì„± ë“±)
  â†’ í™˜ê²½ íŠ¹ì´ì : ê° 100-200ê°œ
  â†’ í˜ˆë¥˜ íŠ¹ì´ì : Capsule biosynthesis (cap5A-P)
  â†’ ì„¸í¬ ë‚´ íŠ¹ì´ì : Iron acquisition (isdA, isdB)
  â†’ ì¡°ì§ íŠ¹ì´ì : Biofilm (icaADBC), Adhesion (fnbA, clfA)

ì½ê¸° ì‹œê°„: 60ë¶„ (ëŒ€ìš©ëŸ‰ ë°ì´í„° ë¶„ì„)
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (Tn-seq ì—°êµ¬ì í•„ìˆ˜)
```

```
ğŸ“„ Kim JH, et al., Lee W* (2024)
"Reducing Peptidoglycan Crosslinking by Chemical Modulator Reverts
 Î²-lactam Resistance in MRSA"
Advanced Sciences. Jul;11(28):e2400858

í•µì‹¬ ë‚´ìš©:
- PG crosslinkingì„ ë‚®ì¶”ë©´ Î²-lactamì´ ë‹¤ì‹œ íš¨ê³¼ ìˆìŒ
- Chemical modulator: ê¸°ì¡´ FDA ìŠ¹ì¸ ì•½ë¬¼ ìŠ¤í¬ë¦¬ë‹
- Lead compound: Î²-lactam MICë¥¼ 64ë°° ê°ì†Œ
- Mechanism: Transpeptidase í™œì„± ì¡°ì ˆ (PBP2aëŠ” ì•„ë‹˜)
- In vivo: MRSA í”¼ë¶€ ê°ì—¼ ëª¨ë¸ì—ì„œ ë³‘ë³€ í¬ê¸° 70% â†“

ì½ê¸° ì‹œê°„: 45ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (Î²-lactam repurposing)
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**ì£¼ì œ**: S. aureusì˜ í™˜ê²½ ì ì‘ê³¼ ì‹ ê·œ ì¹˜ë£Œ í‘œì 

**ë‹¤ë£° ë‚´ìš© (ì˜ˆìƒ)**:

```
1. S. aureus ê°ì—¼ì˜ ë‹¤ì–‘ì„±
   - í‘œë©´ ê°ì—¼: í”¼ë¶€, ìƒì²˜ (ë…ì†Œ, adhesion)
   - ì¹¨ìŠµ ê°ì—¼: í˜ˆë¥˜, ì¥ê¸° (ë©´ì—­ íšŒí”¼, ì¡°ì§ ì¹¨íˆ¬)
   - ë§Œì„± ê°ì—¼: Biofilm, ì„¸í¬ ë‚´ (persister, dormancy)

   - í•­ìƒì œ ì„ íƒì˜ ë”œë ˆë§ˆ:
     â†’ Vancomycin: í˜ˆë¥˜ ì¢‹ìŒ, ì¡°ì§ ë‚˜ì¨
     â†’ Rifampin: ì¡°ì§ ì¢‹ìŒ, ë‹¨ë… ì‚¬ìš© ë¶ˆê°€ (ë‚´ì„± ë¹ ë¦„)
     â†’ Daptomycin: í˜ˆë¥˜ ì¢‹ìŒ, íë ´ ì•ˆ ë¨ (surfactant ì–µì œ)

2. Transposon sequencing ë°©ë²•ë¡ 
   - Principle:
     â†’ Mariner transposon (ë¬´ì‘ìœ„ ì‚½ì…)
     â†’ Genomic DNA ë¶„ë¦¬ â†’ ì‚½ì… ë¶€ìœ„ sequencing
     â†’ Read count â†“ = í•„ìˆ˜ ìœ ì „ì (mutant ìƒì¡´ ëª»í•¨)

   - Workflow:
     1. Tn library ì œì‘ (10,000+ mutants)
     2. íŠ¹ì • í™˜ê²½ ì ‘ì¢… (in vitro, in vivo)
     3. ìƒì¡´ mutant DNA ì¶”ì¶œ
     4. Illumina sequencing (>50M reads)
     5. Bioinformatics: Essential gene calling

   - ì¥ì : Genome-wide, unbiased, quantitative
   - ë‹¨ì : Redundant geneì€ ê²€ì¶œ ì–´ë ¤ì›€

3. í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ì ë¶„ì„ ê²°ê³¼
   - ê³µí†µ í•„ìˆ˜ ìœ ì „ì (287ê°œ):
     â†’ DNA replication (polC, dnaA)
     â†’ Protein synthesis (ribosomal proteins)
     â†’ Cell wall synthesis (mur operon)
     â†’ Central metabolism (TCA cycle, glycolysis)
     â†’ **ì˜ë¯¸**: ê¸°ì¡´ í•­ìƒì œ í‘œì ê³¼ ê²¹ì¹¨ (ê²€ì¦)

   - í˜ˆë¥˜ íŠ¹ì´ì  (134ê°œ):
     â†’ Capsule (cap operon): ë³´ì²´ íšŒí”¼
     â†’ Coagulase (coa): í˜ˆì „ í˜•ì„±
     â†’ Protein A (spa): IgG Fc ê²°í•©
     â†’ **ì˜ë¯¸**: ë©´ì—­ íšŒí”¼ ë©”ì»¤ë‹ˆì¦˜ì´ í•µì‹¬

   - ì„¸í¬ ë‚´ íŠ¹ì´ì  (156ê°œ):
     â†’ Iron acquisition (isd operon)
     â†’ Phagosome escape (hemolysins)
     â†’ Autophagy evasion (ì¼ë¶€ ë¯¸ê·œëª…)
     â†’ **ì˜ë¯¸**: ì˜ì–‘ íšë“ê³¼ ë…ì†Œê°€ í•µì‹¬

   - ì¡°ì§ íŠ¹ì´ì  (ë¶€ìœ„ë§ˆë‹¤ ë‹¤ë¦„):
     â†’ í: Biofilm (icaADBC), toxin (Panton-Valentine)
     â†’ ë¼ˆ: Adhesion (fnbA, clfA), invasion (fnbB)
     â†’ ì‹¬ì¥: Clumping factor (clfA), fibronectin binding

4. ì‹ ê·œ í‘œì  ê²€ì¦ ë° ì•½ë¬¼ ê°œë°œ
   - í‘œì  1: DHQD (3-Dehydroquinate Dehydratase)
     â†’ Shikimate pathway íš¨ì†Œ (ì¸ê°„ ì—†ìŒ)
     â†’ ëª¨ë“  í™˜ê²½ì—ì„œ í•„ìˆ˜
     â†’ ì–µì œì œ: Competitive inhibitor (Km = 54 Î¼M)

   - í‘œì  2: Sortase A (SrtA)
     â†’ í‘œë©´ ë‹¨ë°±ì§ˆ anchoring
     â†’ Biofilm, ì¡°ì§ ê°ì—¼ì— í•„ìˆ˜
     â†’ ì–µì œì œ: Small molecule (IC50 = 2.3 Î¼M)

   - í‘œì  3: PG crosslinking modulator
     â†’ Î²-lactam ì¬í™œìš© ì „ëµ
     â†’ MRSAì— íš¨ê³¼
     â†’ ê¸°ì¡´ ì•½ë¬¼ repurposing (FDA ìŠ¹ì¸ ì•½ë¬¼ í™œìš©)

   - í‘œì  4: Serine hydrolases (ì‹ ê·œ, 2024 Dec)
     â†’ Virulence factor í™œì„±í™”
     â†’ Biofilm 70% ì–µì œ
     â†’ Fluorosulfate covalent inhibitors
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "S. aureus ê°ì—¼ì€ í•˜ë‚˜ê°€ ì•„ë‹ˆë‹¤"
- "ë¶€ìœ„ë³„ í•„ìˆ˜ ìœ ì „ì = ë¶€ìœ„ë³„ ì¹˜ë£Œ í‘œì "
- "Tn-seqì€ ìƒˆë¡œìš´ í‘œì  ë°œêµ´ì˜ gold standard"

**ë°©ë²•ë¡  (ì˜ˆìƒ)**:
- **Tn-seq library**: ~10,000 mutants, Mariner transposon
- **In vivo models**:
  - Sepsis: Tail vein injection (LD50 ëª¨ë¸)
  - Lung: Intranasal inoculation
  - Bone: Tibial injection
- **Bioinformatics**: DESeq2, EdgeR (differential essentiality)
- **Target validation**: Gene knockout, complementation, in vivo efficacy

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì´ ë°œí‘œê°€ ë„ì›€ì´ ë˜ëŠ” ê²½ìš°**:

1. **í•­ìƒì œ ê°œë°œì** (í‘œì  ë°œêµ´)
   - Tn-seq ë°ì´í„°ë¡œ ì‹ ê·œ í‘œì  ë¦¬ìŠ¤íŠ¸ í™•ë³´
   - í™˜ê²½ íŠ¹ì´ì  í‘œì ìœ¼ë¡œ "ë§ì¶¤ í•­ìƒì œ" ê°œë°œ
   - ê¸°ì¡´ í‘œì  ì¬ê²€ì¦ (í™˜ê²½ë³„ í•„ìˆ˜ì„± í™•ì¸)

2. **ê°ì—¼ë³‘ ì—°êµ¬ì** (ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜)
   - S. aureusê°€ ê° ì¡°ì§ì—ì„œ ì‚¬ìš©í•˜ëŠ” ìƒì¡´ ì „ëµ ì´í•´
   - Biofilm, ì„¸í¬ ë‚´ ìƒì¡´, ë©´ì—­ íšŒí”¼ ë©”ì»¤ë‹ˆì¦˜
   - ë™ë¬¼ ëª¨ë¸ ì„ íƒ ê°€ì´ë“œ (ë¶€ìœ„ë³„ ê°ì—¼ ëª¨ë¸)

3. **ìœ ì „ì²´í•™ ì—°êµ¬ì** (ë°©ë²•ë¡ )
   - Tn-seq ì‹¤í—˜ ë””ìì¸ (library í¬ê¸°, sequencing depth)
   - Bioinformatics pipeline (essential gene calling)
   - ë‹¤ë¥¸ ì„¸ê· ì— ì ìš© (E. coli, P. aeruginosa, Mycobacterium)

4. **í¬ë‹¥ ì—°êµ¬ì** (í•™ê³„-ì‚°ì—… ì—°ê³„)
   - Target validation workflow (genetic â†’ biochemical â†’ in vivo)
   - Drug screening platform êµ¬ì¶•
   - IP ì „ëµ (novel target, lead compound)

**ì‘ìš© ê°€ëŠ¥ì„±**:

- **Precision antibiotics**: ë¶€ìœ„ë³„ íŠ¹ì´ì  ì¹˜ë£Œì œ
  - í˜ˆë¥˜ ê°ì—¼: Capsule ì–µì œì œ
  - ë¼ˆ ê°ì—¼: Adhesion ì–µì œì œ + biofilm disruptor
  - í ê°ì—¼: Toxin ì¤‘í™” + biofilm ì œê±°

- **Drug repurposing**: ê¸°ì¡´ FDA ì•½ë¬¼ ìŠ¤í¬ë¦¬ë‹
  - PG crosslinking modulator (Î²-lactam ì¬í™œìš©)
  - DHQD ì–µì œì œ (ê¸°ì¡´ íš¨ì†Œ ì–µì œì œ ë¼ì´ë¸ŒëŸ¬ë¦¬)

- **Companion diagnostics**: ê°ì—¼ ë¶€ìœ„ í™•ì¸ â†’ ìµœì  í•­ìƒì œ ì„ íƒ

**ê¸°ìˆ  ì´ì „ ê°€ëŠ¥ì„±**:

- **Tn-seq í”Œë«í¼**: ë‹¤ë¥¸ ë³‘ì›ì²´ì— ì ìš© (ë¼ì´ì„ ì‹±)
- **Target database**: í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ì DB (êµ¬ë… ëª¨ë¸)
- **Lead compounds**: Sortase A, DHQD ì–µì œì œ (íŠ¹í—ˆ, ê³µë™ ê°œë°œ)

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

1. **Tn-seqì—ì„œ "í•„ìˆ˜"ì˜ ê¸°ì¤€ì€ ë¬´ì—‡ì¸ê°€?**
   - **ë°°ê²½**: Read count cutoff, FDR (false discovery rate)
   - **ì˜ë„**: í†µê³„ì  ì—„ê²©ì„± ì´í•´

2. **Redundant gene familyëŠ” ì–´ë–»ê²Œ ë‹¤ë£¨ëŠ”ê°€?**
   - **ë°°ê²½**: Adhesin ë“± ì—¬ëŸ¬ paralogs ì¡´ì¬
   - **ì˜ˆìƒ ë‹µë³€**: Combinatorial knockout, CRISPRië¡œ ê²€ì¦

3. **ì¸ê°„ ì¡°ì§ê³¼ ë™ë¬¼ ëª¨ë¸ì˜ ì°¨ì´ëŠ”?**
   - **ë°°ê²½**: ë§ˆìš°ìŠ¤ vs. ì¸ê°„ ë©´ì—­ê³„, ì¡°ì§ êµ¬ì¡°
   - **ì˜ë„**: ì„ìƒ relevance í™•ì¸

**ê¸°ìˆ ì  ì§ˆë¬¸**:

1. **Tn libraryì˜ í¬í™”ë„ëŠ”?** (ìœ ì „ìë‹¹ í‰ê·  ëª‡ ê°œ insertion?)
2. **In vivo Tn-seq ì‹œ input library í¬ê¸°ëŠ”?** (bottleneck ë¬¸ì œ)
3. **Sequencing depthëŠ”?** (reads per sample, coverage)

**ì‘ìš© ê´€ë ¨**:

1. **DHQD ì–µì œì œ ê°œë°œ ì§„í–‰ ìƒí™©ì€?** (lead compound, ì„ìƒ ì „ ë‹¨ê³„?)
2. **Sortase A ì–µì œì œì™€ ê¸°ì¡´ í•­ìƒì œ ë³‘ìš© ì‹œë„ˆì§€ëŠ”?**
3. **ë¶€ìœ„ë³„ íŠ¹ì´ì  ì¹˜ë£Œì œê°€ í˜„ì‹¤í™”ë  ì‹œê¸°ëŠ”?** (5ë…„? 10ë…„?)

**ë¹„íŒì  ì§ˆë¬¸** (ì‹ ì¤‘íˆ):

1. **Tn-seqì€ ì„±ì¥ í•„ìˆ˜ ìœ ì „ìë§Œ ì°¾ëŠ”ë°, virulence factorëŠ”?**
   - ê°€ëŠ¥í•œ í›„ì† ì§ˆë¬¸: "Tn-seq + infection model ì¡°í•© ì „ëµì€?"

2. **ë§ˆìš°ìŠ¤ ëª¨ë¸ì˜ í•œê³„ëŠ”?** (ì¸ê°„ ì¡°ì§ê³¼ ë‹¤ë¥¸ ìƒë¦¬)
   - ì˜ˆ: ë§ˆìš°ìŠ¤ëŠ” capsule ì¤‘ìš”ë„ ë‚®ìŒ (ì¸ê°„ì€ ë†’ìŒ)

---

## ğŸ§  ì„¸ì…˜ ì „ì²´ í•µì‹¬ ìš”ì•½

### 10ê°€ì§€ í•µì‹¬ ë©”ì‹œì§€

1. **"í•­ì‚°ê· "ì€ í•˜ë‚˜ê°€ ì•„ë‹ˆë‹¤: Mtb â‰  MAC**
   - MtbëŠ” Type I IFN ì•…ìš©, neutrophil ë™ì›
   - MACëŠ” ì§€ë°©ì‚° ëŒ€ì‚¬ êµë€, dendritic cell ì–µì œ
   - ì¹˜ë£Œ ì „ëµ: MtbëŠ” IFN ì°¨ë‹¨, MACëŠ” ëŒ€ì‚¬ ì¡°ì ˆ

2. **í•œêµ­ì—ì„œ NTM ê°ì—¼ì´ ê¸‰ì¦í•˜ê³  ìˆë‹¤**
   - 2014ë…„ 2.7% â†’ 2019ë…„ 4.8% (NTM ë¶„ë¦¬ìœ¨)
   - M. avium (41%), M. intracellulare (38%), M. abscessus (9%)
   - ê³ ë ¹í™”, ë§Œì„± íì§ˆí™˜ ì¦ê°€ê°€ ì£¼ìš” ì›ì¸

3. **Host-directed therapy (HDT)ëŠ” ë¯¸ë˜ê°€ ì•„ë‹Œ í˜„ì¬ë‹¤**
   - JAK inhibitorë¡œ Type I IFN ì°¨ë‹¨ (Mtb)
   - STING agonist (c-di-GMP)ë¡œ ë°±ì‹  íš¨ê³¼ ê°•í™”
   - PPAR agonistë¡œ MAC ê°ìˆ˜ì„± ê°ì†Œ

4. **ROSëŠ” "ë…"ì´ ì•„ë‹ˆë¼ "ì•½"ì´ ë  ìˆ˜ ìˆë‹¤**
   - Pharmacophore ì„¤ê³„ë¡œ ì„¸ê·  ë‚´ë¶€ì—ì„œë§Œ ROS ìƒì„±
   - Organoruthenium complex: ê·¸ëŒì–‘ì„±ê·  íŠ¹ì´ì 
   - Quinone redox cycling: ê´‘ë²”ìœ„ í•­ê·  íš¨ê³¼

5. **ROS ê¸°ë°˜ ì¹˜ë£ŒëŠ” ë‚´ì„±ì´ ìƒê¸°ê¸° ì–´ë µë‹¤**
   - ë¹„íŠ¹ì´ì  ì‚°í™” ì†ìƒ (DNA, protein, lipid ëª¨ë‘)
   - ë‹¨ì¼ ëŒì—°ë³€ì´ë¡œ ì €í•­ì„± íšë“ ë¶ˆê°€
   - MDR, XDR ì„¸ê· ì—ë„ íš¨ê³¼

6. **Phage + ROS ê²°í•©ì€ ì°¨ì„¸ëŒ€ ì¹˜ë£Œ ì˜µì…˜**
   - Designer phageë¡œ Cas9 + ROS generator ì „ë‹¬
   - ì´ì¤‘ íƒ€ê²©: í•„ìˆ˜ ìœ ì „ì ì ˆë‹¨ + ì‚°í™” ìŠ¤íŠ¸ë ˆìŠ¤
   - ì„ íƒì  ì œê±° (íŠ¹ì • ì„¸ê· ë§Œ, ì •ìƒ ê· ì´ ë³´ì¡´)

7. **S. aureusëŠ” í™˜ê²½ë§ˆë‹¤ ë‹¤ë¥¸ "ì–¼êµ´"ì„ ê°€ì§„ë‹¤**
   - í˜ˆë¥˜: Capsule, ë©´ì—­ íšŒí”¼ í•„ìˆ˜
   - ì„¸í¬ ë‚´: ì²  íšë“, autophagy íšŒí”¼ í•„ìˆ˜
   - ì¡°ì§: Biofilm, adhesion í•„ìˆ˜

8. **Transposon sequencingì€ ì‹ ê·œ í‘œì  ë°œêµ´ì˜ gold standard**
   - Genome-wide, unbiased, quantitative
   - í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ì map ì™„ì„±
   - 287ê°œ ê³µí†µ í•„ìˆ˜ + 100-200ê°œ í™˜ê²½ íŠ¹ì´ì 

9. **ë¶€ìœ„ë³„ ë§ì¶¤ í•­ìƒì œ(precision antibiotics)ê°€ ì˜¨ë‹¤**
   - í˜ˆë¥˜ ê°ì—¼: Capsule ì–µì œì œ
   - ë¼ˆ ê°ì—¼: Adhesion ì–µì œì œ
   - í ê°ì—¼: Biofilm disruptor + toxin ì¤‘í™”

10. **ê¸°ì¡´ ì•½ë¬¼ ì¬í™œìš©(drug repurposing)ì´ ë¹ ë¥¸ ê¸¸**
    - PG crosslinking modulator (FDA ìŠ¹ì¸ ì•½ë¬¼)
    - Î²-lactamì„ MRSAì— ë‹¤ì‹œ ì‚¬ìš© ê°€ëŠ¥
    - DHQD, Sortase A ì–µì œì œ (ê¸°ì¡´ ë¼ì´ë¸ŒëŸ¬ë¦¬ í™œìš©)

### ì„¸ì…˜ í›„ ì–»ê²Œ ë  í†µì°°

**ê³¼í•™ì **:
- ë³‘ì›ì„± ì„¸ê· ì˜ ë©´ì—­ íšŒí”¼ ë©”ì»¤ë‹ˆì¦˜ì´ ê· ì¢…ë§ˆë‹¤, í™˜ê²½ë§ˆë‹¤ ë‹¤ë¦„
- ROSëŠ” ì‚´ê·  ë©”ì»¤ë‹ˆì¦˜ì´ì§€ë§Œ, ì„ íƒì„± ì¡°ì ˆì´ í•µì‹¬
- Tn-seqìœ¼ë¡œ ì–»ì€ í•„ìˆ˜ ìœ ì „ì ì •ë³´ëŠ” ì¹˜ë£Œ í‘œì ì˜ ë³´ë¬¼ ì°½ê³ 

**ê¸°ìˆ ì **:
- Host-directed therapy ì„¤ê³„ ë°©ë²• (ë©´ì—­ ì¡°ì ˆì œ + í•­ìƒì œ ë³‘ìš©)
- Pharmacophore ê¸°ë°˜ ROS generator ì„¤ê³„ ì›ë¦¬
- Tn-seq ì‹¤í—˜ ë””ìì¸ ë° bioinformatics workflow

**ì‘ìš©ì **:
- ê²°í•µ/NTM ì¹˜ë£Œì— ë©´ì—­ ì¡°ì ˆì œ ë„ì… ê°€ëŠ¥ì„±
- Topical ROS ì¹˜ë£Œì œ (ìƒì²˜, í™”ìƒ ê°ì—¼)
- S. aureus ê°ì—¼ ë¶€ìœ„ë³„ ìµœì  í•­ìƒì œ ì„ íƒ ì „ëµ

**ê°œì¸ì ** (í¬ë‹¥ ì—°êµ¬ì):
- í•™ì œê°„ ìœµí•© ì—°êµ¬ì˜ ì¤‘ìš”ì„± (ë©´ì—­í•™ + ëŒ€ì‚¬í•™, í™”í•™ + ë¯¸ìƒë¬¼í•™, ìœ ì „ì²´í•™ + ê°ì—¼ë³‘í•™)
- ê¸°ì´ˆ-ì„ìƒ-ì‚°ì—… ì—°ê³„ ì—°êµ¬ ëª¨ë¸ (Shin, Cho, Lee ê·¸ë£¹ ëª¨ë‘)
- êµ­ì œ í˜‘ë ¥ ë° ë‹¤í•™ì œ íŒ€ êµ¬ì„± ì „ëµ

---

## ğŸ“š ì‚¬ì „ ì½ê¸° ìë£Œ

### í•„ìˆ˜ ë¦¬ë·° ë…¼ë¬¸ (ë°°ê²½ ì´í•´ìš©)

#### 1. Mycobacterial Pathogenesis ì´í•´

```
ğŸ“„ Kwon KW, Choi H, et al., Shin SJ* (2025)
"A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease:
 A 2025 Update for Clinicians and Scientists"
PubMed ID: 40062355

í•µì‹¬ ë‚´ìš©:
- 2024ë…„ TB/NTM ì—°êµ¬ ë™í–¥ ì´ì •ë¦¬ (10,000+ ë…¼ë¬¸ ë¦¬ë·°)
- Mtb vs. NTM ë³‘ì›ì„± ì°¨ì´
- ìƒˆë¡œìš´ ì§„ë‹¨ë²• (Xpert MTB/RIF Ultra, LAM assays)
- ì¹˜ë£Œì œ ê°œë°œ í˜„í™© (bedaquiline, delamanid, pretomanid)
- Host-directed therapy ì „ëµ

ì½ê¸° ì‹œê°„: 90ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### 2. ROS-based Antibacterial Therapy ì´í•´

```
ğŸ“„ Cho Y-H*, et al. (2024)
"Reactive Oxygen Species (ROS)-Mediated Antibacterial Oxidative Therapies:
 Available Methods to Generate ROS and a Novel Option Proposal"
Int J Mol Sci. 25(13):7182

í•µì‹¬ ë‚´ìš©:
- ROS ìƒë¬¼í•™ ê¸°ì´ˆ
- 6ê°€ì§€ ROS ìƒì„± ë°©ë²• ë¹„êµ
- ì„ìƒ ì‘ìš© í˜„í™© (FDA ìŠ¹ì¸ ì œí’ˆ)
- ì‹ ê·œ pharmacophore ì ‘ê·¼ë²•
- ì¥ë‹¨ì  ë° ë¯¸ë˜ ë°©í–¥

ì½ê¸° ì‹œê°„: 40ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### 3. S. aureus Genomics ì´í•´

```
ğŸ“„ Chang J, et al., Lee W* (2025)
"Environmental fitness of different host niches shape the survival fitness
 of Staphylococcus aureus"
Nature Communications. 16(1):6928

í•µì‹¬ ë‚´ìš©:
- Tn-seq ë°©ë²•ë¡  ìƒì„¸
- 9ê°œ ê°ì—¼ í™˜ê²½ ë¹„êµ
- í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ì 287ê°œ + íŠ¹ì´ì  ìœ ì „ì
- ì‹ ê·œ ì¹˜ë£Œ í‘œì  ì œì•ˆ
- Precision antibiotics ê°œë…

ì½ê¸° ì‹œê°„: 60ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### 4. AMR ìœ„ê¸°ì™€ ëŒ€ì‘ ì „ëµ (ë°°ê²½)

```
ğŸ“„ WHO (2024)
"Antimicrobial Resistance: Global Report on Surveillance"

í•µì‹¬ ë‚´ìš©:
- 2050ë…„ê¹Œì§€ ì—°ê°„ 1,000ë§Œ ëª… ì‚¬ë§ ì˜ˆìƒ
- ESKAPE ë³‘ì›ì²´ (E. faecium, S. aureus, K. pneumoniae,
  A. baumannii, P. aeruginosa, Enterobacter)
- One Health ì ‘ê·¼ì˜ í•„ìš”ì„±
- ì‹ ê·œ í•­ìƒì œ íŒŒì´í”„ë¼ì¸ í˜„í™©

ì½ê¸° ì‹œê°„: 30ë¶„ (ìš”ì•½ë³¸)
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜†
```

### ì—°ì‚¬/ê¸°ê´€ ì—°êµ¬ (ì—…ì  íŒŒì•…ìš©)

**ì „ëµ**:
- Google Scholarì—ì„œ "Sung Jae Shin Yonsei tuberculosis" ê²€ìƒ‰
- PubMedì—ì„œ "You-Hee Cho CHA reactive oxygen" ê²€ìƒ‰
- "Wonsik Lee Sungkyunkwan Staphylococcus" ê²€ìƒ‰

**ì¶”ì • ì£¼ìš” ë…¼ë¬¸**:

```
1. Shin SJ: Nature Communications, J Adv Res (ìµœê·¼ 5ë…„)
   â†’ Mtb/MAC ë°±ì‹ , HDT, ë©´ì—­ ì¡°ì ˆ

2. Cho YH: JACS Au, J Virol, J Microbiol (2021-2025)
   â†’ ROS pharmacophores, designer phage, P. aeruginosa

3. Lee W: Nature Communications, Advanced Sciences (2024-2025)
   â†’ Tn-seq, MRSA í‘œì , PG modulation
```

### ì‚°ì—… ë™í–¥ ë¦¬í¬íŠ¸

#### ì‹œì¥ ë¶„ì„

```
ğŸ“Š Global Market Insights (2024)
"Antimicrobial Resistance Market Size, Share & Trends Analysis Report"

ë‚´ìš©:
- AMR ì¹˜ë£Œì œ ì‹œì¥: $2024ë…„ $12.5B â†’ 2030ë…„ $18.7B
- ì£¼ìš” íŒŒì´í”„ë¼ì¸:
  - Novel Î²-lactamase inhibitors (Venatorx, Entasis)
  - Siderophore-antibiotic conjugates (Shionogi)
  - Phage therapy (Adaptive Phage, Locus Bio)
- íˆ¬ì ë™í–¥: Biotech íˆ¬ì ê°ì†Œ, public funding ì¦ê°€

ì ‘ê·¼: ì˜¨ë¼ì¸ êµ¬ë… ë˜ëŠ” ëŒ€í•™ ë„ì„œê´€
```

### ëŒ€ì¤‘ ê³¼í•™ (ì‰¬ìš´ ì´í•´ìš©)

```
ğŸ“– "The Killer Within: The Deadly Rise of Drug-Resistant Bacteria"
    - Mark J. Plotkin & Michael Shnayerson (2002, updated 2013)

- AMR ìœ„ê¸°ë¥¼ ì¼ë°˜ì¸ë„ ì´í•´í•  ìˆ˜ ìˆê²Œ ì„¤ëª…
- MRSA, VRE, CRE ë“± ì£¼ìš” ë‚´ì„±ê·  ì‚¬ë¡€
- í•­ìƒì œ ê°œë°œì˜ ì—­ì‚¬ì™€ ë¯¸ë˜

â†’ ë°°ê²½ ì§€ì‹ í•¨ì–‘ì— ì¢‹ìŒ (í•™ìƒ, ì¼ë°˜ì¸)
```

---

## ğŸ¤ ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸

### ê³¼í•™ì  ì§ˆë¬¸ (ì—°êµ¬ì/í•™ìƒìš©)

#### Mycobacterial Pathogenesis

**Q1**: C3H/HeJ ë§ˆìš°ìŠ¤ì™€ A/J ë§ˆìš°ìŠ¤ì—ì„œ ê´€ì°°ëœ ë©´ì—­ ë°˜ì‘ ì°¨ì´ê°€ ì¸ê°„ í™˜ìì—ì„œë„ ì¬í˜„ë˜ëŠ”ê°€?

**ë°°ê²½**: ë§ˆìš°ìŠ¤ ëª¨ë¸ì€ ìœ ìš©í•˜ì§€ë§Œ, ì¸ê°„ ê²°í•µì˜ ìœ¡ì•„ì¢… í˜•ì„±ì„ ì™„ì „íˆ ì¬í˜„í•˜ì§€ ëª»í•¨

**Q2**: Type I IFN ì°¨ë‹¨ì œ(JAK inhibitor)ë¥¼ Mtb í™˜ìì—ê²Œ ì‚¬ìš© ì‹œ, ë‹¤ë¥¸ ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼(COVID-19, influenza) ìœ„í—˜ì€ ì–´ë–»ê²Œ ê´€ë¦¬í•˜ëŠ”ê°€?

**Q3**: MAC í™˜ìì˜ ì§€ë°©ì‚° ëŒ€ì‚¬ profileì„ ì¸¡ì •í•˜ì—¬ ì¹˜ë£Œ ë°˜ì‘ì„ ì˜ˆì¸¡í•  ìˆ˜ ìˆëŠ”ê°€?

**ë°°ê²½**: Precision medicine ì ‘ê·¼ - ë°”ì´ì˜¤ë§ˆì»¤ ê¸°ë°˜ ì¹˜ë£Œ ì„ íƒ

**Q4**: Dendritic cell vaccineì˜ í•­ì›ìœ¼ë¡œ HSP90-Ag85B-MPT64-Rv2190cë¥¼ ì„ íƒí•œ ê·¼ê±°ëŠ” ë¬´ì—‡ì¸ê°€?

**ë°°ê²½**: ìˆ˜ì²œ ê°œ í›„ë³´ í•­ì› ì¤‘ ì„ íƒ ê¸°ì¤€ ì´í•´

#### ROS-based Therapy

**Q5**: Organoruthenium complexì˜ ê·¸ëŒì–‘ì„±ê·  íŠ¹ì´ì„±ì„ ê²°ì •í•˜ëŠ” êµ¬ì¡°ì  íŠ¹ì§•ì€ ë¬´ì—‡ì¸ê°€?

**ë°°ê²½**: Ligand ì„¤ê³„ë¡œ ê·¸ëŒìŒì„±ê· ê¹Œì§€ í™•ì¥ ê°€ëŠ¥í•œì§€

**Q6**: ROS-generating pharmacophoreì™€ ê¸°ì¡´ í•­ìƒì œ(Î²-lactam, fluoroquinolone) ë³‘ìš© ì‹œ ì‹œë„ˆì§€ íš¨ê³¼ê°€ ìˆëŠ”ê°€?

**Q7**: Phage + ROS ë³µí•© ì¹˜ë£Œì—ì„œ ROSê°€ phage ìì²´ë¥¼ ì†ìƒì‹œí‚¤ì§€ ì•ŠëŠ”ê°€?

**ë°°ê²½**: Phage DNA/proteinë„ ROSì— ë¯¼ê°

**Q8**: ì„¸ê· ì˜ SOS response (DNA ì†ìƒ ë³µêµ¬ ì‹œìŠ¤í…œ)ê°€ ROS ì¹˜ë£Œì˜ íš¨ê³¼ë¥¼ ê°ì†Œì‹œí‚¬ ìˆ˜ ìˆëŠ”ê°€?

#### S. aureus Targets

**Q9**: Transposon sequencingì—ì„œ ë°œê²¬í•œ "í™˜ê²½ íŠ¹ì´ì  í•„ìˆ˜ ìœ ì „ì"ê°€ ì‹¤ì œë¡œ ê·¸ í™˜ê²½ì—ì„œë§Œ í•„ìˆ˜í•œì§€, ë‹¤ë¥¸ ì¡°ê±´ì—ì„œëŠ” ì–´ë–¤ ì—­í• ì„ í•˜ëŠ”ê°€?

**Q10**: DHQD ì–µì œì œê°€ ì¸ê°„ ì¥ë‚´ ë¯¸ìƒë¬¼ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì€?

**ë°°ê²½**: Shikimate pathwayëŠ” ë§ì€ ì„¸ê· ì´ ê°€ì§€ê³  ìˆìŒ (dysbiosis ìš°ë ¤)

**Q11**: Sortase A ì–µì œì œê°€ S. aureusì˜ virulenceë¥¼ ë‚®ì¶”ëŠ” ê²ƒì€ í™•ì¸í–ˆëŠ”ë°, ì‹¤ì œ ê°ì—¼ ëª¨ë¸ì—ì„œ ìƒì¡´ìœ¨ì„ ë†’ì´ëŠ”ê°€?

**ë°°ê²½**: Virulence attenuation â‰  therapeutic efficacy

**Q12**: PG crosslinking modulatorë¥¼ ì‚¬ìš©í•˜ë©´ Î²-lactamì˜ MICê°€ ë‚®ì•„ì§€ëŠ”ë°, ì´ê²ƒì´ ëª¨ë“  Î²-lactamì— ì ìš©ë˜ëŠ”ê°€? (penicillin, cephalosporin, carbapenem ë“±)

### ê¸°ìˆ /ë°©ë²•ë¡  ì§ˆë¬¸

**Q13**: Aerosol ê°ì—¼ ëª¨ë¸ì—ì„œ ê°ì—¼ ìš©ëŸ‰(CFU)ì„ ì–´ë–»ê²Œ í‘œì¤€í™”í•˜ëŠ”ê°€?

**ë°°ê²½**: ì‹¤í—˜ ì¬í˜„ì„± í™•ë³´ì— ì¤‘ìš”

**Q14**: Lipidomics ë¶„ì„ ì‹œ í ì¡°ì§ì˜ ì§€ë°©ì‚°ì„ ì¶”ì¶œí•˜ëŠ” í”„ë¡œí† ì½œì€?

**Q15**: Organoruthenium complexì˜ í•©ì„± ìˆ˜ìœ¨ê³¼ ìˆœë„ëŠ”? (ëŒ€ëŸ‰ ìƒì‚° ê°€ëŠ¥ì„±)

**Q16**: Transposon library ì œì‘ ì‹œ transposon insertionì˜ randomnessë¥¼ ì–´ë–»ê²Œ ê²€ì¦í•˜ëŠ”ê°€?

**Q17**: In vivo Tn-seq ì‹¤í—˜ì—ì„œ input library í¬ê¸°ê°€ ì‘ìœ¼ë©´ bottleneck ë¬¸ì œê°€ ìƒê¸°ëŠ”ë°, ìµœì†Œ ëª‡ ë§ˆë¦¬ì˜ ë§ˆìš°ìŠ¤ê°€ í•„ìš”í•œê°€?

**Q18**: Designer phageì— Cas9ì„ ì‚½ì…í•  ë•Œ phage íŒ¨í‚¤ì§• í¬ê¸° ì œí•œì€ ì–´ë–»ê²Œ ê·¹ë³µí•˜ëŠ”ê°€?

**ë°°ê²½**: Phage head í¬ê¸° í•œê³„ (~50 kb)

### ì‘ìš©/ì‚°ì—… ì§ˆë¬¸

**Q19**: Host-directed therapy (JAK inhibitor, STING agonist)ì˜ ì„ìƒì‹œí—˜ ê³„íšì´ ìˆëŠ”ê°€? PhaseëŠ”?

**Q20**: Organoruthenium complexì˜ topical formulation (gel, cream)ì€ ê°œë°œ ì¤‘ì¸ê°€?

**Q21**: S. aureus ë¶€ìœ„ë³„ ë§ì¶¤ í•­ìƒì œë¥¼ ì‹¤ì œë¡œ ê°œë°œí•˜ë ¤ë©´, ê°ì—¼ ë¶€ìœ„ë¥¼ ì–´ë–»ê²Œ ì‹ ì†íˆ ì§„ë‹¨í•˜ëŠ”ê°€?

**ë°°ê²½**: Companion diagnostics í•„ìš”

**Q22**: PG crosslinking modulator + Î²-lactam ë³‘ìš© ìš”ë²•ì˜ íŠ¹í—ˆ ìƒí™©ì€?

**Q23**: Transposon sequencing ë°ì´í„°ë¥¼ ìƒì—…í™”í•  ê³„íšì´ ìˆëŠ”ê°€? (íƒ€ê²Ÿ DB êµ¬ë… ì„œë¹„ìŠ¤ ë“±)

### êµìœ¡/ì§„ë¡œ ì§ˆë¬¸ (í•™ìƒ/í¬ë‹¥ìš©)

**Q24**: Host-directed therapy ì—°êµ¬ë¥¼ ì‹œì‘í•˜ë ¤ëŠ” í•™ìƒì—ê²Œ ì¶”ì²œí•˜ëŠ” ì²« í”„ë¡œì íŠ¸ëŠ”?

**Q25**: ë¯¸ìƒë¬¼í•™ ì „ê³µìê°€ ìœ ê¸°ê¸ˆì†í™”í•™(organoruthenium)ì„ ë°°ìš°ë ¤ë©´ ì–´ë–¤ ê²½ë¡œë¥¼ ì¶”ì²œí•˜ëŠ”ê°€?

**ë°°ê²½**: í•™ì œê°„ ì—°êµ¬ë¥¼ ìœ„í•œ êµìœ¡

**Q26**: Transposon sequencing ê¸°ìˆ ì„ ìµíˆë ¤ë©´ ì–´ë–¤ êµìœ¡ ê³¼ì •ì´ë‚˜ workshopì„ ì¶”ì²œí•˜ëŠ”ê°€?

**Q27**: ê¸°ì´ˆ ì—°êµ¬(ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜)ì™€ ì‚°ì—… ì‘ìš©(ì•½ë¬¼ ê°œë°œ)ì„ ì—°ê²°í•˜ëŠ” ê²½í—˜ì„ ìŒ“ìœ¼ë ¤ë©´ ì–´ë–¤ í™˜ê²½(í•™ê³„, ì‚°ì—…ê³„, êµ­ë¦½ì—°êµ¬ì†Œ)ì´ ì¢‹ì€ê°€?

### ì² í•™ì /ë¯¸ë˜ ì§€í–¥ì  ì§ˆë¬¸

**Q28**: í•­ìƒì œ ë‚´ì„± ìœ„ê¸°ë¥¼ ê·¼ë³¸ì ìœ¼ë¡œ í•´ê²°í•˜ë ¤ë©´, ì‹ ì•½ ê°œë°œë³´ë‹¤ "í•­ìƒì œ ì‚¬ìš© ê°ì†Œ" ì „ëµì´ ë” ì¤‘ìš”í•œê°€?

**Q29**: Precision antibiotics (ë¶€ìœ„ë³„ ë§ì¶¤ ì¹˜ë£Œ)ê°€ í˜„ì‹¤í™”ë˜ë ¤ë©´, í˜„ì¬ ì˜ë£Œ ì‹œìŠ¤í…œì—ì„œ ì–´ë–¤ ë³€í™”ê°€ í•„ìš”í•œê°€?

**ë°°ê²½**: ì‹ ì† ì§„ë‹¨, ê·œì œ, ë³´í—˜ ì ìš© ë“±

**Q30**: ROS ê¸°ë°˜ ì¹˜ë£Œê°€ ê´‘ë²”ìœ„í•˜ê²Œ ì‚¬ìš©ë˜ë©´, ì„¸ê· ì´ ê²°êµ­ "ROS ì €í•­ì„±"ì„ íšë“í•  ê°€ëŠ¥ì„±ì€?

---

## ğŸ¤ ë„¤íŠ¸ì›Œí‚¹ ìš°ì„ ìˆœìœ„

### Tier 1: ìµœìš°ì„  ì»¨íƒ

#### Sung Jae Shin (Yonsei University)

**ë°°ê²½**:
- Professor, Department of Microbiology, Institute for Immunology and Immunological Diseases
- ì—°êµ¬ ë¶„ì•¼: Mycobacterial pathogenesis, vaccine development, host-directed therapy
- ì£¼ìš” ì—…ì :
  - Nature Communications, J Adv Res (2024-2025)
  - BCG+booster vaccine ê°œë°œ (multivalent subunit)
  - Type I IFN pathway ì—°êµ¬ (Mtb/MAC ì°¨ì´)

**ì™œ ì¤‘ìš”í•œê°€**:
- í•œêµ­ ê²°í•µ/NTM ì—°êµ¬ì˜ ìµœê³  ê¶Œìœ„ì
- Host-directed therapy ë¶„ì•¼ ì„ ë„
- êµ­ì œ í˜‘ë ¥ ê²½í—˜ í’ë¶€ (Infection Control Research Group Leader)

**ì ‘ê·¼ ì „ëµ**:

```
íƒ€ì´ë°:
- ë°œí‘œ ì§í›„ ì§ˆì˜ì‘ë‹µ ì‹œ ì§ˆë¬¸ (1-2ê°œ)
- ì„¸ì…˜ ì¢…ë£Œ í›„ ê°œì¸ì ìœ¼ë¡œ ì ‘ê·¼ (5ë¶„ ì´ë‚´ ì§§ê²Œ)
- Follow-up ì´ë©”ì¼ (ë‹¹ì¼ ì €ë… ë˜ëŠ” ë‹¤ìŒ ë‚ )

ì¤€ë¹„:
- ë³¸ì¸ ì—°êµ¬ì™€ì˜ ì—°ê²°ì  ëª…í™•íˆ (ì˜ˆ: ë©´ì—­ ì¡°ì ˆ, ë°±ì‹  adjuvant)
- Shin ê·¸ë£¹ì˜ ìµœê·¼ ë…¼ë¬¸ 1-2í¸ ì½ê¸° (Nature Commun 2025)
- êµ¬ì²´ì  í˜‘ë ¥ ì•„ì´ë””ì–´ (ë°©ë²•ë¡  êµí™˜, ê³µë™ ì—°êµ¬)

Follow-up:
- ëª…í•¨ êµí™˜
- ì´ë©”ì¼ë¡œ ê°„ë‹¨í•œ ê°ì‚¬ + ë³¸ì¸ ì—°êµ¬ ì†Œê°œ (1 í˜ì´ì§€ ìš”ì•½)
- Lab visit ìš”ì²­ (YonseiëŠ” ì„œìš¸ ì†Œì¬, ì ‘ê·¼ ì‰¬ì›€)
```

**ë…¼ì˜ ì£¼ì œ** (ê²½ë ¥ë³„):

- **í•™ìƒ**:
  - Mtb/MAC ë§ˆìš°ìŠ¤ ëª¨ë¸ training ê°€ëŠ¥ì„±
  - ë©´ì—­ ë¶„ì„ í”„ë¡œí† ì½œ (Flow cytometry panel)
  - ì„ë°•ì‚¬ ì§„í•™ / ì¸í„´ì‹­

- **í¬ë‹¥**:
  - Host-directed therapy ê³µë™ ì—°êµ¬
  - Dendritic cell vaccine ê¸°ìˆ  ì´ì „
  - Grant ê³µë™ ì‹ ì²­ (NRF, KHIDI)

- **ì‚°ì—…ê³„**:
  - HDT í›„ë³´ ë¬¼ì§ˆ in vivo ê²€ì¦
  - Vaccine adjuvant ë¼ì´ì„ ì‹±
  - Clinical trial partnership

#### You-Hee Cho (CHA University)

**ë°°ê²½**:
- Professor, Department of Pharmacy, CHA University
- ì—°êµ¬ ë¶„ì•¼: ROS-mediated antibacterials, phage engineering, synthetic microbiology
- ì£¼ìš” ì—…ì :
  - JACS Au (2021): Organoruthenium complex
  - Int J Mol Sci (2024): ROS therapy ë¦¬ë·°
  - Pseudomonas ì œì–´ ì „ë¬¸ê°€

**ì™œ ì¤‘ìš”í•œê°€**:
- ROS pharmacophore ì„¤ê³„ ë…ë³´ì  ì „ë¬¸ì„±
- Phage + chemical ìœµí•© ì—°êµ¬ ì„ ë„
- ì‚°í•™ ì—°ê³„ ê²½í—˜ (ì‹ ì•½ ê°œë°œ ê°€ëŠ¥ì„±)

**ì ‘ê·¼ ì „ëµ**:

```
íƒ€ì´ë°:
- ë°œí‘œ ì¤‘ í¥ë¯¸ë¡œìš´ ìŠ¬ë¼ì´ë“œ ì‚¬ì§„ (ë‚˜ì¤‘ì— ì´ë©”ì¼ reference)
- ì§ˆì˜ì‘ë‹µ ì‹œ êµ¬ì²´ì  ê¸°ìˆ  ì§ˆë¬¸
- Break time (13:25-13:40) ë˜ëŠ” ì„¸ì…˜ í›„

ì¤€ë¹„:
- Organoruthenium complex í•©ì„± ê¸°ì´ˆ ì´í•´
- ROS ì¸¡ì • ë°©ë²• (DCFH-DA, DHE) ìˆ™ì§€
- Phage therapy ê·œì œ í˜„í™© íŒŒì•… (í•œêµ­, ë¯¸êµ­)

Follow-up:
- Collaboration inquiry (ROS assay í™œìš©, compound ì œê³µ)
- CHA University Lab visit (ê²½ê¸°ë„ í¬ì²œ - ì•½ê°„ ë©€ì§€ë§Œ ê°€ì¹˜ ìˆìŒ)
- ê³µë™ grant (KHIDI ê°ì—¼ë³‘ ì¹˜ë£Œì œ ê°œë°œ ê³¼ì œ)
```

**ë…¼ì˜ ì£¼ì œ**:

- **í™”í•™ ì „ê³µì**:
  - Metal complex í•©ì„± í”„ë¡œí† ì½œ
  - Ligand ì„¤ê³„ ì „ëµ (ì„ íƒì„± ì¡°ì ˆ)
  - Scale-up ê°€ëŠ¥ì„±

- **ë¯¸ìƒë¬¼ ì „ê³µì**:
  - ROS ì¸¡ì • í”Œë«í¼ êµ¬ì¶•
  - Biofilm assay í”„ë¡œí† ì½œ
  - Designer phage ì œì‘ ê¸°ìˆ 

- **ì•½í•™/ì‚°ì—…ê³„**:
  - Topical formulation ê°œë°œ
  - Pharmacokinetics, toxicology
  - IP ì „ëµ ë° ë¼ì´ì„ ì‹±

#### Wonsik Lee (Sungkyunkwan University)

**ë°°ê²½**:
- Associate Professor, School of Pharmacy, SKKU
- ì—°êµ¬ ë¶„ì•¼: S. aureus genomics, Tn-seq, novel antibiotic targets
- ì£¼ìš” ì—…ì :
  - Nature Communications (2025): S. aureus Tn-seq
  - Advanced Sciences (2024): MRSA Î²-lactam repurposing
  - Transposon sequencing ì „ë¬¸ê°€

**ì™œ ì¤‘ìš”í•œê°€**:
- Tn-seq êµ­ë‚´ ìµœê³  ì „ë¬¸ê°€
- S. aureus ì‹ ê·œ í‘œì  ë‹¤ìˆ˜ ë³´ìœ  (IP)
- ì‚°ì—… ì—°ê³„ í™œë°œ (ì•½ë¬¼ ê°œë°œ íŒŒì´í”„ë¼ì¸)

**ì ‘ê·¼ ì „ëµ**:

```
íƒ€ì´ë°:
- ë°œí‘œ í›„ Tn-seq ë°©ë²•ë¡  êµ¬ì²´ì  ì§ˆë¬¸
- ì„¸ì…˜ ì¢…ë£Œ í›„ ë˜ëŠ” Panel Discussion (17:55-18:30) ì‹œ
- ì €ë… ì‹ì‚¬ / Networking event (ìˆë‹¤ë©´)

ì¤€ë¹„:
- Nature Commun 2025 ë…¼ë¬¸ ì •ë… (Tn-seq 9ê°œ í™˜ê²½)
- Bioinformatics ê¸°ì´ˆ (essential gene calling)
- ë³¸ì¸ ê´€ì‹¬ ë³‘ì›ì²´ì— Tn-seq ì ìš© ê°€ëŠ¥ì„± ìƒê°

Follow-up:
- SKKU Lab visit ìš”ì²­ (ìˆ˜ì› - ì„œìš¸ì—ì„œ 1ì‹œê°„)
- Tn-seq í˜‘ë ¥ ë…¼ì˜ (ë‹¤ë¥¸ ë³‘ì›ì²´ ì ìš©)
- Target validation ê³µë™ ì—°êµ¬
```

**ë…¼ì˜ ì£¼ì œ**:

- **ìœ ì „ì²´í•™ ì—°êµ¬ì**:
  - Tn-seq library ì œì‘ í”„ë¡œí† ì½œ
  - Bioinformatics pipeline (DESeq2, EdgeR)
  - ë‹¤ë¥¸ ë³‘ì›ì²´ ì ìš© (E. coli, P. aeruginosa)

- **ì•½ë¬¼ ê°œë°œì**:
  - DHQD, Sortase A ì–µì œì œ lead compounds
  - In vivo efficacy ë°ì´í„°
  - Co-development, licensing

- **í¬ë‹¥**:
  - Postdoc position ë¬¸ì˜
  - Grant ê³µë™ ì‹ ì²­
  - Training (Tn-seq, target validation)

### Tier 2: ê´€ë ¨ ë¶„ì•¼ ì—°êµ¬ì

#### ì„±ê· ê´€ëŒ€ / ì—°ì„¸ëŒ€ / CHA ëŒ€í•™ ì—°êµ¬ì

**ì°¾ëŠ” ë²•**:
- ì„¸ì…˜ ì¤‘ ì²­ì¤‘ ê´€ì°° (ëˆ„ê°€ ì ê·¹ì ìœ¼ë¡œ ì§ˆë¬¸í•˜ëŠ”ì§€)
- Poster session (ìˆë‹¤ë©´) ë°©ë¬¸
- í•™íšŒ í”„ë¡œê·¸ë¨ì—ì„œ ì†Œì† í™•ì¸

**ë„¤íŠ¸ì›Œí‚¹ í¬ì¸íŠ¸**:
- ê°™ì€ ëŒ€í•™ / ì¸ê·¼ ì§€ì—­ â†’ ì •ê¸° ë¯¸íŒ… ê°€ëŠ¥
- ì‹œì„¤ ê³µìœ  (BSL-3, ì¥ë¹„)
- Journal club, seminar êµë¥˜

#### ê²°í•µ/NTM ì—°êµ¬ì (êµ­ë‚´)

**ì£¼ìš” ê¸°ê´€**:
- êµ­ë¦½ë³´ê±´ì—°êµ¬ì› (ì§ˆë³‘ê´€ë¦¬ì²­)
- ëŒ€í•œê²°í•µí˜‘íšŒ (Korean Institute of Tuberculosis)
- ì„œìš¸ëŒ€, ê°€í†¨ë¦­ëŒ€, ìš¸ì‚°ëŒ€ (ê°ì—¼ë‚´ê³¼, ë¯¸ìƒë¬¼í•™ê³¼)

**ë„¤íŠ¸ì›Œí‚¹ ì „ëµ**:
- ì„ìƒ ë°ì´í„° ì ‘ê·¼ ê°€ëŠ¥ì„±
- í™˜ì ìƒ˜í”Œ í˜‘ë ¥ ì—°êµ¬
- ì •ë¶€ ê³¼ì œ ê³µë™ ì‹ ì²­

#### í•­ìƒì œ ê°œë°œ ì—°êµ¬ì

**ì°¾ëŠ” ë²•**:
- Session 4 (Antibiotic Development) ì°¸ì„ì
- ì œì•½íšŒì‚¬ / ë°”ì´ì˜¤í… ì†Œì† í™•ì¸
- LinkedIn ê²€ìƒ‰ (IAMRT 2025 ì°¸ì„ì)

**ë„¤íŠ¸ì›Œí‚¹ í¬ì¸íŠ¸**:
- In vitro â†’ in vivo ì—°ê²°
- Lead compound optimization
- Preclinical development partnership

### Tier 3: ì‚°ì—…ê³„ ì¸ì‚¬

#### ì œì•½íšŒì‚¬ / ë°”ì´ì˜¤í…

**íƒ€ê²Ÿ**:
- êµ­ë‚´: ì¢…ê·¼ë‹¹, ìœ í•œì–‘í–‰, SKë°”ì´ì˜¤íŒœ, ì…€íŠ¸ë¦¬ì˜¨
- í•´ì™¸: GSK, Pfizer, Merck (í•œêµ­ ì§€ì‚¬)
- Biotech: CAMP Therapeutics (ë°œí‘œì Jaehoon Yu), A&J Science (ë°œí‘œì Hee-Jong Hwang)

**ì ‘ê·¼**:
- Business card êµí™˜
- ê¸°ìˆ  ì´ì „ ê°€ëŠ¥ì„± íƒ€ì§„
- Co-development ë…¼ì˜ (NDA í•„ìš” ì‹œ í›„ì† ì¡°ì¹˜)

#### CRO / CDO (Contract Research/Development Organization)

**ì—­í• **:
- Preclinical efficacy í…ŒìŠ¤íŠ¸
- PK/PD ë¶„ì„
- Regulatory consulting

**ë„¤íŠ¸ì›Œí‚¹ ì „ëµ**:
- ì„œë¹„ìŠ¤ ì œê³µ ê°€ëŠ¥ ë²”ìœ„ íŒŒì•…
- ë¹„ìš© / ê¸°ê°„ ê²¬ì 
- í–¥í›„ í˜‘ë ¥ ê°€ëŠ¥ì„±

### ë„¤íŠ¸ì›Œí‚¹ ì‹¤ì „ íŒ

**ëª…í•¨**:
- ìµœì†Œ 30ì¥ ì¤€ë¹„ (ì—¬ìœ  ìˆê²Œ)
- ì˜ë¬¸ ëª…í•¨ í•„ìˆ˜ (í•œê¸€ ë’·ë©´)
- QR code (ì—°êµ¬ì‹¤ í™ˆí˜ì´ì§€, Google Scholar) í¬í•¨í•˜ë©´ ì¢‹ìŒ

**Elevator Pitch (30ì´ˆ ìê¸°ì†Œê°œ)**:

```
í…œí”Œë¦¿:
"ì•ˆë…•í•˜ì„¸ìš”, [ì´ë¦„]ì…ë‹ˆë‹¤. [ì†Œì†]ì—ì„œ [ì§ìœ„]ë¡œ [ì£¼ì œ] ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.
 íŠ¹íˆ [êµ¬ì²´ì  ê¸°ìˆ /ëª¨ë¸]ì„ ì‚¬ìš©í•´ì„œ [ëª©í‘œ]ë¥¼ ë‹¬ì„±í•˜ë ¤ê³  í•©ë‹ˆë‹¤.
 ì˜¤ëŠ˜ ë°œí‘œì—ì„œ [ì—°ì‚¬ ì´ë¦„]ë‹˜ì˜ [íŠ¹ì • ë‚´ìš©]ì´ ì œ ì—°êµ¬ì™€ ì—°ê²°ë  ê²ƒ ê°™ì•„ì„œ,
 [í˜‘ë ¥/ì§ˆë¬¸] ê°€ëŠ¥ì„±ì„ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤."

ì˜ˆì‹œ (í•™ìƒ):
"ì•ˆë…•í•˜ì„¸ìš”, ê¹€ì² ìˆ˜ì…ë‹ˆë‹¤. ì„œìš¸ëŒ€ ë¯¸ìƒë¬¼í•™ê³¼ ë°•ì‚¬ê³¼ì •ìƒì´ê³ ,
 ê²°í•µê· ì˜ granuloma í˜•ì„± ë©”ì»¤ë‹ˆì¦˜ì„ ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.
 íŠ¹íˆ 3D organoid ëª¨ë¸ì„ ê°œë°œ ì¤‘ì¸ë°,
 ì˜¤ëŠ˜ Shin êµìˆ˜ë‹˜ì˜ dendritic cell vaccine ì´ì•¼ê¸°ê°€ ì €í¬ ëª¨ë¸ì—
 ì ìš© ê°€ëŠ¥í•  ê²ƒ ê°™ì•„ì„œ, í˜‘ë ¥ ê°€ëŠ¥ì„±ì„ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤."

ì˜ˆì‹œ (í¬ë‹¥):
"ì•ˆë…•í•˜ì„¸ìš”, ì´ì˜í¬ì…ë‹ˆë‹¤. KAISTì—ì„œ í¬ë‹¥ìœ¼ë¡œ
 í•­ìƒì œ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ì„ transcriptomicsë¡œ ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.
 Lee êµìˆ˜ë‹˜ì˜ Tn-seq ë°ì´í„°ì™€ ì €í¬ RNA-seq ë°ì´í„°ë¥¼ í†µí•©í•˜ë©´
 S. aureus í™˜ê²½ë³„ ìœ ì „ì ë°œí˜„ mapì„ ë§Œë“¤ ìˆ˜ ìˆì„ ê²ƒ ê°™ì•„ì„œ,
 ê³µë™ ì—°êµ¬ë¥¼ ì œì•ˆë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤."

ì˜ˆì‹œ (ì‚°ì—…ê³„):
"ì•ˆë…•í•˜ì„¸ìš”, ë°•ë¯¼ìˆ˜ì…ë‹ˆë‹¤. [íšŒì‚¬ëª…]ì—ì„œ í•­ê· ì œ ê°œë°œ PMìœ¼ë¡œ ì¼í•˜ê³  ìˆìŠµë‹ˆë‹¤.
 Cho êµìˆ˜ë‹˜ì˜ organoruthenium complexê°€ ì €í¬ íŒŒì´í”„ë¼ì¸ì—
 ì í•©í•´ ë³´ì—¬ì„œ, in vivo efficacy dataì™€ IP ìƒí™©ì„ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤."
```

**Follow-up ì´ë©”ì¼ í…œí”Œë¦¿**:

```
Subject: IAMRT 2025ì—ì„œ ëµ™ê²Œ ë˜ì–´ ì˜ê´‘ì´ì—ˆìŠµë‹ˆë‹¤ - [ê·€í•˜ì˜ ì´ë¦„]

Dear Professor [ì—°ì‚¬ ì´ë¦„],

10ì›” 30ì¼ IAMRT 2025 Session 2ì—ì„œ "[ë°œí‘œ ì œëª©]" ë°œí‘œë¥¼
ë§¤ìš° í¥ë¯¸ë¡­ê²Œ ë“¤ì—ˆìŠµë‹ˆë‹¤.

ì €ëŠ” [ì†Œì†]ì—ì„œ [ì—°êµ¬ ì£¼ì œ]ë¥¼ ì—°êµ¬í•˜ê³  ìˆëŠ” [ì´ë¦„]ì…ë‹ˆë‹¤.
íŠ¹íˆ ì„ ìƒë‹˜ì˜ [êµ¬ì²´ì  ë‚´ìš©, ì˜ˆ: Type I IFN pathway ì—°êµ¬]ê°€
ì €í¬ [í”„ë¡œì íŠ¸/ëª¨ë¸]ê³¼ ì—°ê²°ë  ìˆ˜ ìˆì„ ê²ƒ ê°™ì•„ ì—°ë½ë“œë¦½ë‹ˆë‹¤.

ì €í¬ëŠ” í˜„ì¬ [ê°„ë‹¨í•œ ì—°êµ¬ ì†Œê°œ, 2-3ë¬¸ì¥]ë¥¼ ì§„í–‰ ì¤‘ì´ë©°,
ì„ ìƒë‹˜ì˜ [ë°©ë²•/ì‹œì•½/ëª¨ë¸]ì„ í™œìš©í•˜ê±°ë‚˜,
í˜¹ì€ ê³µë™ ì—°êµ¬ë¥¼ í†µí•´ [ëª©í‘œ]ë¥¼ ë‹¬ì„±í•˜ê³ ì í•©ë‹ˆë‹¤.

ì²¨ë¶€í•œ 1-page summaryì— ì €í¬ ì—°êµ¬ë¥¼ ê°„ëµíˆ ì •ë¦¬í–ˆìŠµë‹ˆë‹¤.
ì‹œê°„ì´ ë˜ì‹ ë‹¤ë©´, Zoom ë¯¸íŒ…ì´ë‚˜ ì—°êµ¬ì‹¤ ë°©ë¬¸ì„ í†µí•´
í˜‘ë ¥ ê°€ëŠ¥ì„±ì„ ë…¼ì˜í•  ìˆ˜ ìˆì„ê¹Œìš”?

ê°ì‚¬í•©ë‹ˆë‹¤.

Best regards,
[ì´ë¦„]
[ì§ìœ„]
[ì†Œì†]
[ì´ë©”ì¼]
[ì „í™”ë²ˆí˜¸]
[Google Scholar / Lab website]
```

---

## âš¡ ì„¸ì…˜ ë‹¹ì¼ ì²´í¬ë¦¬ìŠ¤íŠ¸

### ì‚¬ì „ ì¤€ë¹„ (D-1: 10ì›” 29ì¼)

#### ì§€ì‹ ì¤€ë¹„

- [ ] ì´ ë°°ê²½ ìë£Œ 2ì°¨ ì •ë… ì™„ë£Œ
- [ ] 3ê°œ ë°œí‘œë³„ë¡œ ì§ˆë¬¸ 1ê°œì”© ì¤€ë¹„ (ì´ 3ê°œ)
- [ ] ì—°ì‚¬ ìµœê·¼ ë…¼ë¬¸ abstract ì½ê¸°
  - [ ] Shin SJ: Nature Commun 2025
  - [ ] Cho YH: Int J Mol Sci 2024
  - [ ] Lee W: Nature Commun 2025
- [ ] ë³¸ì¸ ì—°êµ¬ì™€ ì—°ê²°ì  ì •ë¦¬ (A4 1ì¥)
- [ ] Elevator pitch ì—°ìŠµ (30ì´ˆ, ê±°ìš¸ ì•ì—ì„œ)

#### ë¬¼ë¦¬ì  ì¤€ë¹„

- [ ] ëª…í•¨ 30ì¥ ì¤€ë¹„ (ì˜ë¬¸ í¬í•¨)
- [ ] ë…¸íŠ¸ë¶ / íƒœë¸”ë¦¿ ì¶©ì „ (ë©”ëª¨ìš©)
- [ ] ë³¼íœ, ë…¸íŠ¸ (ì¢…ì´ ë©”ëª¨ ì„ í˜¸ ì‹œ)
- [ ] íœ´ëŒ€í° ì¶©ì „ (QR code ëª…í•¨, ì‚¬ì§„ ì´¬ì˜ìš©)
- [ ] ì„¸ì…˜ ì‹œê°„ ì•ŒëŒ ì„¤ì • (13:30)
- [ ] ì ì‹¬ ì‹ì‚¬ ê³„íš (12:10-13:40, ê°„ë‹¨íˆ)
- [ ] êµí†µí¸ í™•ì¸ (ì„±ê· ê´€ëŒ€ ì˜ê³¼ëŒ€í•™ ìœ„ì¹˜, 3304í˜¸ ê°•ì˜ì‹¤)

### ì„¸ì…˜ ì¤‘ (13:40-14:55)

#### ì ê·¹ì  ì²­ì·¨

- [ ] ë°œí‘œ ì‹œì‘ ì „ ì•ìë¦¬ í™•ë³´ (ì§ˆë¬¸ ì‹œ ëˆˆì— ë„ê²Œ)
- [ ] ìŠ¬ë¼ì´ë“œ ì¤‘ í•µì‹¬ ê·¸ë¦¼/í‘œ ì‚¬ì§„ ì´¬ì˜ (ë‚˜ì¤‘ì— ì´ë©”ì¼ reference)
- [ ] ì´í•´ ì•ˆ ë˜ëŠ” ìš©ì–´ ì‹¤ì‹œê°„ ë©”ëª¨
- [ ] ì—°ì‚¬ê°€ ê°•ì¡°í•˜ëŠ” í¬ì¸íŠ¸ ì²´í¬ (ëª©ì†Œë¦¬ í†¤, ë°˜ë³µ)
- [ ] ë³¸ì¸ ì—°êµ¬ì™€ ì—°ê²°ë˜ëŠ” ìˆœê°„ ë©”ëª¨

#### ê´€ì°°

- [ ] ëˆ„ê°€ ì ê·¹ì ìœ¼ë¡œ ì§ˆë¬¸í•˜ëŠ”ì§€ ê´€ì°° (ë‚˜ì¤‘ì— ë„¤íŠ¸ì›Œí‚¹)
- [ ] ì—°ì‚¬ì˜ body language (ì—´ì •, ìì‹ ê° â†’ í˜‘ë ¥ ê°€ëŠ¥ì„±)
- [ ] ì²­ì¤‘ ë°˜ì‘ (ì–´ë–¤ ë‚´ìš©ì— ê³µê°/í¥ë¯¸)

### ì§ˆì˜ì‘ë‹µ (ê° ë°œí‘œ í›„ 5ë¶„)

#### ì „ëµ

- [ ] ì§ˆë¬¸ íƒ€ì´ë° ì„ íƒ:
  - [ ] ì²« ë²ˆì§¸ ì§ˆë¬¸ (ëˆˆì— ë„ì§€ë§Œ ë¶€ë‹´)
  - [ ] ë‘ì„¸ ë²ˆì§¸ ì§ˆë¬¸ (ì ë‹¹, ì¶”ì²œ)
  - [ ] ë§ˆì§€ë§‰ ì§ˆë¬¸ (ì‹œê°„ ë¶€ì¡± ìœ„í—˜)
- [ ] ì§ˆë¬¸ ì‹œ ìê¸°ì†Œê°œ ê°„ë‹¨íˆ (ì´ë¦„, ì†Œì†)
- [ ] ì§ˆë¬¸ í›„ ì¶”ê°€ ë…¼ì˜ëŠ” "ë‚˜ì¤‘ì—" ì•½ì† (ì‹œê°„ ë…ì  ì£¼ì˜)

#### ìƒ˜í”Œ ì§ˆë¬¸ (ì¤€ë¹„í•œ ê²ƒ ì¤‘ ì„ íƒ)

```
Option 1 (ê³¼í•™ì ):
"Shin êµìˆ˜ë‹˜, Type I IFN ì°¨ë‹¨ì„ Mtb ê°ì—¼ 'í›„ 2-4ì£¼'ì— í•˜ì‹ ë‹¤ê³  í•˜ì…¨ëŠ”ë°,
 ì„ìƒì—ì„œëŠ” í™˜ìê°€ ì´ë¯¸ ë§Œì„± ê°ì—¼ ìƒíƒœì¼ í…ë°, ì´ ê²½ìš°ì—ë„ íš¨ê³¼ê°€ ìˆì„ê¹Œìš”?"

Option 2 (ê¸°ìˆ ì ):
"Cho êµìˆ˜ë‹˜, Organoruthenium complexê°€ ê·¸ëŒì–‘ì„±ê· ì— íŠ¹ì´ì ì´ë¼ê³  í•˜ì…¨ëŠ”ë°,
 ê·¸ëŒìŒì„±ê· ê¹Œì§€ í™•ì¥í•˜ë ¤ë©´ ligandë¥¼ ì–´ë–»ê²Œ ìˆ˜ì •í•´ì•¼ í• ê¹Œìš”?"

Option 3 (ì‘ìš©):
"Lee êµìˆ˜ë‹˜, Tn-seqìœ¼ë¡œ ë°œê²¬í•œ í™˜ê²½ íŠ¹ì´ì  ìœ ì „ìë¥¼ ì‹¤ì œ ì•½ë¬¼ í‘œì ìœ¼ë¡œ ë§Œë“¤ ë•Œ,
 ê°€ì¥ í° ë„ì „ ê³¼ì œëŠ” ë¬´ì—‡ì´ê³ , ì–´ë–»ê²Œ ê·¹ë³µí•˜ì…¨ë‚˜ìš”?"
```

### ì„¸ì…˜ ì§í›„ (14:55-15:10, Break time)

#### ì¦‰ì‹œ í–‰ë™

- [ ] ì—°ì‚¬ì—ê²Œ ì§ì ‘ ì ‘ê·¼ (5ë¶„ ì´ë‚´, ê°„ë‹¨íˆ)
- [ ] ëª…í•¨ êµí™˜ + ì§§ì€ ëŒ€í™”
  - "ë°œí‘œ ê°ì‚¬í•©ë‹ˆë‹¤. [êµ¬ì²´ì  ë‚´ìš©]ì´ ì¸ìƒ ê¹Šì—ˆìŠµë‹ˆë‹¤."
  - "ì œ ì—°êµ¬ëŠ” [í•œ ë¬¸ì¥ ìš”ì•½]ì¸ë°, í˜‘ë ¥ ê°€ëŠ¥ì„±ì„ ì´ë©”ì¼ë¡œ ì—¬ì­™ê² ìŠµë‹ˆë‹¤."
- [ ] ì—°ì‚¬ê°€ ë°”ì˜ë©´ ë¬´ë¦¬í•˜ì§€ ë§ê³  ì´ë©”ì¼ë¡œ (ë‹¹ì¼ ë°¤)

#### ê¸°ë¡

- [ ] ë©”ëª¨ ì •ë¦¬ (ë…¸íŠ¸ â†’ ë””ì§€í„¸)
- [ ] ì´¬ì˜í•œ ìŠ¬ë¼ì´ë“œ ì‚¬ì§„ ë°±ì—…
- [ ] ë°›ì€ ëª…í•¨ì— ê°„ë‹¨ ë©”ëª¨ (ì–´ë–¤ ëŒ€í™” í–ˆëŠ”ì§€)
- [ ] ì¶”ê°€ ì§ˆë¬¸ ë– ì˜¤ë¥´ë©´ ì¦‰ì‹œ ê¸°ë¡

### ë‹¹ì¼ ì˜¤í›„/ì €ë…

#### ë„¤íŠ¸ì›Œí‚¹ í™•ì¥

- [ ] Session 3, 4 ì°¸ì„ (ê´€ë ¨ ì—°êµ¬ì ì¶”ê°€ íŒŒì•…)
- [ ] Panel Discussion (17:55-18:30) ì°¸ì„
- [ ] Coffee break / ì €ë… ì‹ì‚¬ ê¸°íšŒ í™œìš©
- [ ] ë‹¤ë¥¸ ì°¸ì„ìì™€ ëŒ€í™” (Tier 2, 3)

#### ì •ë¦¬

- [ ] í•˜ë£¨ ì´ì •ë¦¬ (ë°°ìš´ ì , ë§Œë‚œ ì‚¬ëŒ)
- [ ] Follow-up ì´ë©”ì¼ ì´ˆì•ˆ ì‘ì„± (í”¼ê³¤í•˜ê¸° ì „ì—)
- [ ] ë‚´ì¼ ì„¸ì…˜ (ìˆë‹¤ë©´) ì¤€ë¹„

### D+1 (10ì›” 31ì¼)

- [ ] Follow-up ì´ë©”ì¼ ë°œì†¡ (3ëª… ì—°ì‚¬ + ì¶”ê°€ ë„¤íŠ¸ì›Œí‚¹ ëŒ€ìƒ)
- [ ] ë°›ì€ ëª…í•¨ ë””ì§€í„¸í™” (ìŠ¤ìº” ì•±, ì—°ë½ì²˜ ì €ì¥)
- [ ] LinkedIn ì—°ê²° ìš”ì²­ (ê°„ë‹¨í•œ ë©”ì‹œì§€ ì²¨ë¶€)

### D+7 (11ì›” 6ì¼)

- [ ] ì‚¬ì „ ì½ê¸° ë…¼ë¬¸ ë‹¤ìš´ë¡œë“œ ë° ì½ê¸° ì‹œì‘
- [ ] ì—°ì‚¬ ì‘ë‹µ í™•ì¸ ë° ì¶”ê°€ ì¡°ì¹˜
- [ ] Lab visit ì¼ì • ì¡°ìœ¨ (Yonsei, CHA, SKKU)

---

## ğŸ“Š ì˜ˆìƒ í•™ìŠµ ì„±ê³¼

### ì§€ì‹ ìŠµë“ (Knowledge)

**Level 1: ê¸°ë³¸ ì´í•´** (ëª¨ë“  ì°¸ì„ì)

- [ ] Mtbì™€ MACì˜ ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜ì´ ë‹¤ë¥´ë‹¤ëŠ” ê²ƒì„ ì´í•´
- [ ] ROSê°€ í•­ê·  ì¹˜ë£Œì— ì‚¬ìš©ë  ìˆ˜ ìˆë‹¤ëŠ” ê°œë… ìŠµë“
- [ ] S. aureusê°€ í™˜ê²½ë§ˆë‹¤ ë‹¤ë¥¸ ìƒì¡´ ì „ëµì„ ì‚¬ìš©í•œë‹¤ëŠ” ê²ƒ ì¸ì§€
- [ ] í•œêµ­ì˜ NTM ê°ì—¼ ì¦ê°€ ì¶”ì„¸ ë° ì—­í•™ ë°ì´í„° íŒŒì•…

**Level 2: ë©”ì»¤ë‹ˆì¦˜ ì´í•´** (ì—°êµ¬ì/í•™ìƒ)

- [ ] Type I IFN pathwayê°€ Mtb ê°ì—¼ì—ì„œ ì–‘ë©´ì„±ì„ ê°€ì§€ëŠ” ì´ìœ  ì„¤ëª… ê°€ëŠ¥
- [ ] MAC ê°ì—¼ ì‹œ ì§€ë°©ì‚° ëŒ€ì‚¬ê°€ ì–´ë–»ê²Œ ê°ìˆ˜ì„±ì— ì˜í–¥ì„ ì£¼ëŠ”ì§€ ì´í•´
- [ ] Pharmacophore ê¸°ë°˜ ROS ìƒì„± ë©”ì»¤ë‹ˆì¦˜ (quinone, metal complex)
- [ ] Transposon sequencingìœ¼ë¡œ í•„ìˆ˜ ìœ ì „ìë¥¼ ì°¾ëŠ” ì›ë¦¬
- [ ] í™˜ê²½ë³„ í•„ìˆ˜ ìœ ì „ìê°€ ë‹¤ë¥¸ ì´ìœ  (ì˜ì–‘, ë©´ì—­, ì‚°ì†Œ ë“±)

**Level 3: ì‹¬í™” ì´í•´** (ì „ë¬¸ ì—°êµ¬ì)

- [ ] C3H/HeJ vs. A/J ë§ˆìš°ìŠ¤ ëª¨ë¸ì˜ ë©´ì—­í•™ì  ì°¨ì´ë¥¼ ì„ìƒì— ì ìš©í•˜ëŠ” ì „ëµ
- [ ] Organoruthenium complexì˜ transfer hydrogenation reaction ìƒì„¸
- [ ] S. aureus Tn-seq ë°ì´í„° í•´ì„ (bioinformatics, essential gene calling)
- [ ] Host-directed therapyì™€ ê¸°ì¡´ í•­ìƒì œ ë³‘ìš© ì‹œ ì‹œë„ˆì§€ ë©”ì»¤ë‹ˆì¦˜
- [ ] Precision antibiotics ê°œë°œì„ ìœ„í•œ í‘œì  ì„ íƒ ê¸°ì¤€

### ê¸°ìˆ  ìŠµë“ (Skills)

**ì—°êµ¬ ê¸°ìˆ **:

- [ ] ê²°í•µ/NTM ë§ˆìš°ìŠ¤ ê°ì—¼ ëª¨ë¸ ë””ìì¸ ì „ëµ
- [ ] ROS ì¸¡ì • ë°©ë²• (DCFH-DA, DHE, H2O2 probe)
- [ ] Transposon library ì œì‘ ë° sequencing workflow
- [ ] Bioinformatics (DESeq2, EdgeR for Tn-seq)
- [ ] In vivo efficacy í‰ê°€ (CFU counting, ì¡°ì§ë³‘ë¦¬)

**ë¹„íŒì  ì‚¬ê³ **:

- [ ] ë§ˆìš°ìŠ¤ ëª¨ë¸ì˜ í•œê³„ ì¸ì‹ (ì¸ê°„ê³¼ì˜ ì°¨ì´)
- [ ] In vitro vs. in vivo ê²°ê³¼ í•´ì„ ì‹œ ì£¼ì˜ì 
- [ ] Tn-seq ë°ì´í„°ì˜ false positive/negative ê°€ëŠ¥ì„±
- [ ] ì‹ ê·œ ì¹˜ë£Œ í‘œì ì˜ druggability í‰ê°€ ê¸°ì¤€

**ì˜ì‚¬ì†Œí†µ**:

- [ ] ê³¼í•™ì  ì§ˆë¬¸ êµ¬ì„± ëŠ¥ë ¥ (ëª…í™•, êµ¬ì²´ì , ë‹µë³€ ê°€ëŠ¥)
- [ ] Elevator pitch ì‘ì„± ë° ë°œí‘œ (30ì´ˆ ìê¸°ì†Œê°œ)
- [ ] Follow-up ì´ë©”ì¼ ì‘ì„± (professional, ê°„ê²°)
- [ ] ë„¤íŠ¸ì›Œí‚¹ ëŒ€í™” ê¸°ìˆ  (ì ê·¹ì ì´ë˜ ë°°ë ¤)

### íƒœë„ ë³€í™” (Attitude)

**íŒ¨ëŸ¬ë‹¤ì„ ì „í™˜**:

- [ ] "í•­ìƒì œ = ì„¸ê·  ì£½ì´ëŠ” ì•½"ì—ì„œ "ë©´ì—­ ì¡°ì ˆ + ì„¸ê·  ì œì–´"ë¡œ í™•ì¥
- [ ] "ëª¨ë“  í™˜ê²½ì—ì„œ íš¨ê³¼ ìˆëŠ” ì•½"ì´ ì•„ë‹ˆë¼ "ë¶€ìœ„ë³„ ë§ì¶¤ ì¹˜ë£Œ"
- [ ] "ë‚´ì„± ê·¹ë³µ"ì´ ì•„ë‹ˆë¼ "ë‚´ì„± ìƒê¸°ê¸° ì–´ë ¤ìš´ ë©”ì»¤ë‹ˆì¦˜" ì„ íƒ

**ì§„ë¡œ/ì—°êµ¬ ë°©í–¥**:

- [ ] í•™ì œê°„ ìœµí•© ì—°êµ¬ì˜ ì¤‘ìš”ì„± ì¸ì‹ (ë©´ì—­+ëŒ€ì‚¬, í™”í•™+ë¯¸ìƒë¬¼)
- [ ] ê¸°ì´ˆ-ì„ìƒ-ì‚°ì—… ì—°ê³„ì˜ í•„ìš”ì„± (bench to bedside)
- [ ] êµ­ì œ í˜‘ë ¥ ë° ë„¤íŠ¸ì›Œí‚¹ì˜ ê°€ì¹˜

**ì„ìƒì  íƒœë„** (ì˜ë£Œì¸):

- [ ] ê²°í•µê³¼ NTMì„ ë‹¤ë¥´ê²Œ ì ‘ê·¼í•´ì•¼ í•œë‹¤ëŠ” ì¸ì‹
- [ ] S. aureus ê°ì—¼ ë¶€ìœ„ë¥¼ ê³ ë ¤í•œ í•­ìƒì œ ì„ íƒ
- [ ] Host-directed therapyì˜ ì„ìƒ ì ìš© ê°€ëŠ¥ì„± ê³ ë ¤

### ë„¤íŠ¸ì›Œí¬ í™•ì¥ (Network)

**ì§ì ‘ ì—°ê²°**:

- [ ] 3ëª… ì—°ì‚¬ì™€ ì´ë©”ì¼ ì—°ê²° í™•ë³´
- [ ] ê°™ì€ ë¶„ì•¼ ì—°êµ¬ì 2-3ëª… ëª…í•¨ êµí™˜
- [ ] ì‚°ì—…ê³„ ì¸ì‚¬ 1-2ëª… ì»¨íƒ

**ê°„ì ‘ ì—°ê²°**:

- [ ] ì—°ì‚¬ì˜ ì—°êµ¬ ê·¸ë£¹ (PhD, postdoc) íŒŒì•…
- [ ] í˜‘ë ¥ ê¸°ê´€ (êµ­ë¦½ë³´ê±´ì—°êµ¬ì›, ê²°í•µí˜‘íšŒ ë“±)
- [ ] LinkedInì„ í†µí•œ 2ì°¨ ë„¤íŠ¸ì›Œí¬

### ì‹¤ìš©ì  ì‘ìš© (Application)

**ì—°êµ¬ì**:

- [ ] ë³¸ì¸ ì—°êµ¬ì— ì ìš© ê°€ëŠ¥í•œ ë°©ë²•ë¡  1-2ê°€ì§€ ë„ì… ê³„íš
- [ ] ê³µë™ ì—°êµ¬ ì œì•ˆì„œ ì´ˆì•ˆ ì‘ì„±
- [ ] Grant ì‹ ì²­ ì•„ì´ë””ì–´ (NRF, KHIDI)

**í•™ìƒ**:

- [ ] ë°•ì‚¬/ì„ì‚¬ ì£¼ì œ ì•„ì´ë””ì–´ êµ¬ì²´í™”
- [ ] ì§€ë„êµìˆ˜ì™€ ë…¼ì˜í•  ë‚´ìš© ì •ë¦¬
- [ ] ì¸í„´ì‹­ / Lab rotation ê¸°íšŒ íƒìƒ‰

**ì‚°ì—…ê³„**:

- [ ] ì‹ ê·œ í‘œì  in-licensing ê°€ëŠ¥ì„± í‰ê°€
- [ ] Preclinical development partnership íƒ€ì§„
- [ ] IP landscape ì¡°ì‚¬ ê³„íš

**ì¼ë°˜ì¸** (ê³¼í•™ ì»¤ë®¤ë‹ˆì¼€ì´í„° ë“±):

- [ ] AMR ìœ„ê¸°ë¥¼ ëŒ€ì¤‘ì—ê²Œ ì„¤ëª…í•˜ëŠ” ìƒˆë¡œìš´ ë°©ì‹
- [ ] ê²°í•µ/NTMì˜ ì°¨ì´ë¥¼ ì‰½ê²Œ ì„¤ëª…í•˜ëŠ” ë¹„ìœ 
- [ ] ROS ì¹˜ë£Œì˜ ê°œë…ì„ ì¼ë°˜ì¸ì—ê²Œ ì „ë‹¬

### ì¸¡ì • ê°€ëŠ¥í•œ ì„±ê³¼ ì§€í‘œ

**ì¦‰ì‹œ** (ì„¸ì…˜ í›„ 1ì¼):

- ëª…í•¨ êµí™˜ ìˆ˜: ëª©í‘œ 10ëª… ì´ìƒ
- ì§ˆë¬¸í•œ íšŸìˆ˜: ìµœì†Œ 1íšŒ
- Follow-up ì´ë©”ì¼ ë°œì†¡: 3í†µ (3ëª… ì—°ì‚¬)

**ë‹¨ê¸°** (1ì£¼ì¼):

- ì—°ì‚¬ ì‘ë‹µë¥ : 3ëª… ì¤‘ 2ëª… ì´ìƒ
- ë…¼ë¬¸ ë‹¤ìš´ë¡œë“œ ë° ì½ê¸°: 3í¸ ì´ìƒ
- ë³¸ì¸ ì—°êµ¬ ê³„íš ì—…ë°ì´íŠ¸: 1ê±´

**ì¤‘ê¸°** (1ê°œì›”):

- Lab visit ì‹¤í˜„: 1ê³³ ì´ìƒ (Yonsei, CHA, SKKU)
- ê³µë™ ì—°êµ¬ ì œì•ˆì„œ ì´ˆì•ˆ: 1ê±´
- í•™íšŒ ë°œí‘œ abstract ì‘ì„±: 1ê±´ (ë°°ìš´ ë‚´ìš© ë°˜ì˜)

**ì¥ê¸°** (6ê°œì›”):

- ê³µë™ ì—°êµ¬ ì°©ìˆ˜: 1ê±´
- Grant ì‹ ì²­: 1ê±´ (ê³µë™ ë˜ëŠ” ë‹¨ë…)
- ë…¼ë¬¸ íˆ¬ê³ : 1í¸ (ì„¸ì…˜ì—ì„œ ë°°ìš´ ë°©ë²•ë¡  í™œìš©)
- í›„ì† í•™íšŒ ì°¸ì„: MSK2025 (10ì›”) ë˜ëŠ” êµ­ì œ í•™íšŒ

---

## ğŸ”— ì¶”ê°€ ë¦¬ì†ŒìŠ¤

### ì˜¨ë¼ì¸ ê°•ì˜

- **Coursera**: "Tuberculosis: Diagnostics and Treatment" (Johns Hopkins)
- **iBiology**: "Bacterial Pathogenesis" seminar series
- **YouTube**: "Transposon Sequencing Tutorial" (Theo van Laar)

### íŒŸìºìŠ¤íŠ¸

- **This Week in Microbiology (TWiM)**: Episode on AMR crisis
- **Microbe Talk**: "Staphylococcus aureus: Friend or Foe?"

### ë°ì´í„°ë² ì´ìŠ¤

- **PubMed**: ìµœì‹  ë…¼ë¬¸ ê²€ìƒ‰
- **Google Scholar**: ì—°ì‚¬ ë…¼ë¬¸ citation tracking
- **ClinicalTrials.gov**: HDT, ROS therapy ì„ìƒì‹œí—˜ í˜„í™©

### í•™íšŒ

- **MSK (Korean Society for Microbiology) Annual Meeting**: ë§¤ë…„ 10ì›”
- **ASM Microbe**: ë¯¸êµ­ ë¯¸ìƒë¬¼í•™íšŒ (6ì›”)
- **ICAAC/ICC**: í•­ê· ì œ/í™”í•™ìš”ë²• êµ­ì œí•™íšŒ

---

**ë¬¸ì„œ ì‘ì„±**: 2025-10-29
**ë²„ì „**: 2.0 (Comprehensive Format)
**ì‘ì„±ì**: Conference Preparation System
**í•™íšŒ**: IAMRT 2025

**ì„¸ì…˜ ì°¸ì„ ì „ ì´ ë¬¸ì„œë¥¼ ìµœì†Œ 2íšŒ ì •ë…í•˜ê³ , ì§ˆë¬¸ 3ê°œë¥¼ ì¤€ë¹„í•˜ì„¸ìš”!**

**Good luck and enjoy the session! ğŸ‰ğŸ”¬**